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The ubiquitous monomer, bisphenol A (BPA), is an endocrine active compound 
used in the production of polycarbonate plastics and epoxy resin.  Environmental 
biomonitoring and epidemiology studies report continuous exposure in humans that are 
associated with different adverse health outcomes. Although regulatory agencies are 
concerned with BPA’s potential to harm pregnant women, fetuses, and young children, 
BPA’s toxicity in humans remains highly debated. Animal and in vitro studies support 
BPA exposure-disease relationships, but metabolic, genetic and physiological differences 
ultimately limit translatability to humans. Thus, the objective of this dissertation was to 
identify BPA concentrations and early biological outcomes directly in humans, focusing 




 trimester human clinical specimens 
obtained from a fetal biobank, we hypothesized that BPA concentration and 
biotransformation will differ across age and tissue compartments, altering 
biotransformation programming in the developing fetus. 
The overall goal of this work was to characterize BPA toxicokinetic and 
toxicodynamic profiles that influence tissue-specific BPA biotransformation via 
xenobiotic metabolizing enzymes (XME) and elicit subsequent cellular changes. First, we 
reported BPA concentrations in N=50 fetal liver specimens (total BPA range: below limit 
of quantification - 96.8 ng/g), where the concentration of free BPA was three times that 
of BPA conjugates. Both concentrations and metabolic profiles varied across age with 
significant reduction in BPA-specific XME gene expression of UGT2B15, SULT1A1, and 
STS in fetal versus adult livers. Next, we examined matched fetal liver, kidney, and 
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placenta in N=12 subjects and observed significant tissue-dependent differences in BPA 
concentrations, XME expression profiles, and global DNA methylation. Fetal livers 
exhibited higher BPA concentrations compared to matched tissues; however, XME 
expression profiles suggest an increased likelihood of BPA-glucuronide deconjugation 
and BPA-sulfate conjugation across the fetal compartments. With organ-specific 
differences in the epigenome, only placental global methylation measurements were 
associated with BPA. Finally, we investigated BPA’s role in pathway specific biological 
outcomes and regulation in fetal liver. In particular, we identified 14 different XME 
candidate genes that were down regulated with higher BPA concentrations. After 
identifying common transcription factor binding sites across all candidate gene 
promoters, we reported increased methylation at these functionally relevant sites with 
higher BPA concentrations at several candidate genes.  




 trimester human fetus is exposed to a 
considerable amount of BPA in utero, especially of the active free BPA form. XME 
expression profiles reveal an altered capacity for BPA biotransformation in the fetus 
compared to adults, with distinct metabolic profiles across different tissues. Interestingly, 
higher BPA concentrations in fetal liver were associated with reduced expression of 
novel XME candidate genes mediated by epigenetic mechanisms. These findings indicate 
that environmentally relevant concentrations of BPA, even across a short window of 








1.1 Children’s Environmental Health Relevance 
Since the beginning of the 20
th
 century, newborn and infant mortality has rapidly 
declined as a result of improvements in nutrition, sanitation practices, and infectious 
disease control (K. S. Lee, 2007). Despite these healthcare reforms, pregnancy-related 
complications and infant morbidities still exist in the population today and give rise to 
excessive medical costs. Prematurity and low birth weights are commonly associated 
with neonatal morbidities, contributing to long-term adverse health consequences as well 
as death in children under 5 (Goldenberg & Culhane, 2007). According to the World 
Health Organization, approximately 13 million babies were born prematurely across the 
globe in 2005 and this number is rising (Beck et al., 2010). Although the focus in the last 
century has been on maternal and childhood survival, the current public health issues 
require the need for reduction in newborn morbidities that can influence quality and 
longevity of life. Like many diseases, the determinants of abnormal fetal development 
and birth-related complications are quite complex, influenced by a variety of 
environmental, social, and genetic factors (Gunning-Schepers & Hagen, 1987). Social 
reform and innovative medical practices will continue to benefit maternal and child 
health; however, to apply the best preventative measures, we must first explore gene-
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environment interactions throughout pregnancy to understand early life disease 
etiologies.  
 
Developmental origins of health and disease 
Following a seminal study by Barker and colleagues from the University of 
Southampton in the 1980s, several associations between low birth weight and adult 
chronic diseases such as coronary heart disease, hypertension, and type 2 diabetes have 
been reported (Barker, 2007). These epidemiological studies along with recent animal 
studies support the developmental origins of health and disease (DOHaD) hypothesis. 
The DOHaD hypothesis states that early life exposures to various environmental stressors 
can perturb normal biological programming and these maladaptations can lead to disease 
later in life (Barker, 1990). Malnutrition and infectious agents can influence development 
when exposures occur throughout sensitive windows of development, especially in the 
prenatal, postnatal, and adolescent stages of life. Perturbations at different life stages can 
influence unique physiological processes with effects ranging from metabolic disorders to 
cancer development (Wright & Christiani, 2010). Disease outcomes are dependent on the 
type of insults and timing of exposure in relation to these sensitive windows of 
development.   
With the growing concern over chemicals that are ubiquitous in our environment, 
DOHaD as well as general environmental health research has shifted from the study of 
nutrition and microbial infection to environmental contaminants. In fact, the focus on 
understanding the link between chemical exposures in early life and disease susceptibility 
has led to the development of the large-scale National Children’s Study (Pak & Souders, 
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2012).  My overall dissertation project parallels many of the epidemiological studies in 
children’s environmental health, but focuses on the characterization of chemical exposure 
within the developing human fetus and identification of early genetic and epigenetic 
changes associated with exposure.  Findings from this dissertation help bridge many of 
the knowledge gaps that remain using animal and epidemiological studies, while 
contributing to both human environmental exposure and health risk assessment.  
 
 
1.2 The Vulnerable Human Fetus  
For the proper development of an organism, a sequence of major biological 
processes must take place within a complex milieu. The timing of these events and 
complexity of the biological structures vary across species given the morphological and 
genomic differences (Xue, Yi, Huang, Shi, & Li, 2011); however, general developmental 
and regulatory mechanisms may be well conserved. The human fetus typically gestates 
for 266 days, unlike its rodent counterparts where gestation lasts from 19-23 days. 
Gestation is divided into several stages including fertilization, pre-implantation, post-
implantation, and fetal periods. Seven days after human fertilization, the newly formed 
blastocyst implants into the uterus, marking the beginning of embryogenesis (Downs, 
2008). Once the three germ layers have formed between day 7 to 20, organogenesis takes 
place until week 8 (Jirasek, 2000). These dramatic changes occur throughout the first 
trimester, followed by rapid growth and functional maturation throughout the fetal period 




Vulnerable window of development 
Throughout prenatal development, the most dynamic physiological changes occur 
in the embryonic stage; thus, this sensitive period is most susceptible to many teratogenic 
effects. Embryonic development is normally described using the Carnegie stages (C1-23) 
of development, based on the 23 distinct external appearances of the embryo within the 
first 2 months of conception (O'Rahilly & Muller, 2010). By stages C10-23, genes related 
to “stemness” are down-regulated and those related to differentiation and organ 
development are up-regulated (Xue, et al., 2011). After neurulation, the heart is the first 
organ to develop, followed by liver, adrenal gland, and then kidney (Hill, 2007). Toxic 
environments that coincide with diverse developmental processes throughout 
organogenesis are more likely to cause adverse effects such as interference with proper 
growth trajectories, malformations, or miscarriages (Rutledge, 1997). The exact uterine 
environment necessary for sustaining a healthy human conceptus and the maturing fetus 
is not well defined.  Thus, characterizing both the normal uterine environment and its 
changes will be necessary to understand organ-specific developmental alterations that 
contribute to postnatal morbidity and mortality. 
 
Role of hormones in pregnancy 
Hormones play an important role in the initiation and establishment of 
fertilization, implantation, and other pregnancy-related events, and their regulation has 
been studied extensively in humans. Continuous crosstalk between the maternal and fetal 
endocrine system is necessary for modulating correct metabolic and developmental 
alterations in pregnancy (Feldt-Rasmussen & Mathiesen, 2011).  In the early stages, 
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elevated progesterone and estrogen help prepare the endometrium for blastocyst 
implantation (Halasz & Szekeres-Bartho, 2013). Utilizing stimulatory feedback 
mechanisms, the developing placenta starts to excrete chorionic gonadotropin to prolong 
progesterone activity. The placenta becomes the major site for active steroidogenesis, 
providing precursor molecules to the fetal adrenal gland for the production of important 
hormones like glucocorticoids (Sherwood, 2008). By week 8, the placenta is a 
functionally mature endocrine organ with significant placental secretions that can sustain 
pregnancy despite ovariectomy (Evain-Brion & Malassine, 2003). By the end of 
pregnancy, progesterone concentrations are reduced, accompanied by increased levels of 
estrogen, prostaglandin, oxytocin, and other hormones that help ripen the cervix in 
preparation for parturition (Terzidou, 2007).  Without proper hormonal checks and 
balances, the uterine environment becomes hostile to the fetus, leading to pregnancy 
terminations or morbidity.  
 
Endocrine disruption  
Given the important role of hormones throughout pregnancy, foreign chemicals or 
xenobiotics that mimic or antagonize endogenous steroids can easily modify 
developmental programming and subsequently affect organ function. Endocrine active 
compounds (EACs) are a class of chemicals originally designed for industrial and 
agricultural purposes. EACs can alter normal endocrine function by disrupting hormone 
production and metabolism or by changing hormone distribution throughout the body at 
very low doses (Schug, Janesick, Blumberg, & Heindel, 2011). The compounds use a 
broad spectrum of mechanisms ranging from nuclear receptor signaling to epigenetic 
 
6 
modification to influence the body in a tissue and time-specific manner. Thus, typical 
dose-response curves and toxicological assessments that are routinely used for other 
environmental contaminants have not been useful for EAC research (McLachlan, 2001).  
While EAC-related studies have rapidly grown since the 1990s with emphasis on 
vulnerable windows of development, further research is necessary to characterize low 
dose exposures and biological effects in the developing human fetus. The goal of my 
dissertation project is to fill this knowledge gap in regards to the most controversial EAC, 
bisphenol A.  
 
 
1.3 Bisphenol A and Health 
Bisphenol A: uses and fate  
Bisphenol A (BPA), a synthetic estrogen used in the manufacturing of 
polycarbonate plastics and epoxy resin, is one of the highest production volume 
chemicals worldwide with annual production of more than 8 billion pounds (L. N. 
Vandenberg et al., 2010).  First synthesized in 1891, its estrogenic properties were 
identified in the 1930s with commercial use of epoxy resin beginning in the 1950s.  By 
the 1970s after the discovery of its use for polycarbonate plastic, BPA production in the 
USA reached half a billion pounds (S. A. Vogel, 2009). BPA continues to play a 
fundamental role in the plastics industry with its various desirable properties including 
transparency, high impact strength, malleability, and superior adhesive properties (Ben-
Jonathan & Steinmetz, 1998).  Consumer products that contain BPA include food and 
beverage containers, thermal paper, electronics, medical supplies, building materials, 
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adhesives, and safety and leisure equipments like helmets. BPA exposure from these 
consumer products is continuous and ubiquitous, raising concern for health effects 
especially in vulnerable populations.  
BPA has the ability to leach from these consumer products, creating many 
opportunities for environmental and human exposure. Introduction to high temperatures, 
acidic or basic solutions, and physical damage can lead to the hydrolysis of plastic 
polymers into the estrogenic monomer. Breakdown of BPA has been reported in several 
products including baby bottles, water bottles, polyvinyl chloride (PVC) tubing, and 
plastic containers (Carwile et al., 2009; Lopez-Cervantes & Paseiro-Losada, 2003; 
Mountfort, Kelly, Jickells, & Castle, 1997; Nerin, Fernandez, Domeno, & Salafranca, 
2003; Sajiki & Yonekubo, 2004). BPA can enter our ecosystems when consumer 
products are disposed into wastewater systems and landfills.  There, in the environment, 
BPA containing polymers remain as debris or undergo biodegradation and 
photodegradation (Crain et al., 2007). Environmental contamination can also occur 
through large-scale manufacturing wastes during processing, handling, and transportation 
of the compound; for example, in 1993 approximately 109 tons of BPA was released into 
air, water, and wastewater treatment facilities (Staples, Dorn, Klecka, O'Block, & Harris, 
1998).  
Humans encounter BPA through various routes, but ingestion through dietary 
sources like food packaging and canned beverages are the primary means of BPA 
exposure as determined by dietary intervention studies. In these studies, volunteers who 
were asked to consume a set amount of canned or packaged meals showed increased 
urinary BPA concentrations (Carwile, Ye, Zhou, Calafat, & Michels, 2011), while those 
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asked to eat fresh unprocessed foods had decreased urinary concentrations compared to 
baseline (Rudel et al., 2011). Investigation into the quantification of free BPA in 
foodstuff has revealed significant variation between brands, across food type and 
composition, and from lot-to-lot (Cao et al., 2011; Noonan, Ackerman, & Begley, 2011). 
Other important routes of exposure include inhalation from aerosolized BPA and dermal 
uptake from contact with thermal paper or medical supplies (Biedermann, Tschudin, & 
Grob, 2010; Calafat et al., 2009; Fleisch, Sheffield, Chinn, Edelstein, & Landrigan, 
2010). Since the identification of every unique source of exposure can be difficult, 
environmental and biological specimens like urine have been analyzed to estimate total 
body burden in the population. These studies estimate that human daily intake range from 
0.1-1 µg/kg body weight per day (L. N. Vandenberg, et al., 2010).  
 
Bisphenol A and health effects 
Once in the body, the parent compound (free BPA) is metabolized into inactive 
BPA conjugates in the liver during first pass metabolism (Figure 1.1). In humans, the 
compound has a short half-life of 6 to 43 hours and once metabolized, conjugates are 
excreted mainly through urine (Dybing & Soderlund, 1999a; Volkel, Colnot, Csanady, 
Filser, & Dekant, 2002). Rodent species, on the other hand, excrete BPA conjugates 
through bile and feces; the half-life of BPA may be longer as a result of intestinal 
deconjugation and enterohepatic recirculation (Chapin et al., 2008). Even with rapid 
metabolism and excretion of the estrogenic free BPA species, dozens of studies have 




In the late 1970s, one of the first national BPA studies was conducted by the 
National Cancer Institute and later continued by the National Toxicology Program. The 2 
year study, based on high dose exposures to adult rodent models, found “no convincing 
evidence” for carcinogenicity and provided the basis for the BPA safety standard or 
reference dose that is still used today at 50 µg/kg of body weight per day (Carcinogenesis 
Bioassay of Bisphenol A (CAS No. 80-05-7) in F344 Rats and B6C3F1 Mice (Feed 
Study), 1982). While originally dismissed because of its weak estrogenicity, BPA started 
to become scrutinized for its hormone-like effects as research into EACs gained 
momentum in the 1990s. Challenging the traditional toxicity and regulatory testing 
paradigm, the first BPA toxicity studies reported BPA dependent changes to 
developmental and reproductive endpoints such as prostate weight and mammary 
proliferation using low dose exposures or pregnant rodent models (Colerangle & Roy, 
1997; Nagel et al., 1997). Since then, rodent studies have associated pre- or perinatal 
BPA exposure with altered body weight, impaired brain development, altered 
reproductive function, changes in immune function, metabolism, and increased cancer 
susceptibility along with other chronic diseases (Chapin, et al., 2008; Maffini, Rubin, 
Sonnenschein, & Soto, 2006; Laura N. Vandenberg et al., 2013). Low dose 
concentrations used to expose animals typically fall below the reference dose, but often 
do not reflect environmentally relevant concentrations encountered in a real world 
setting.  
Over the past few years, environmental biomonitoring studies in conjunction with 
epidemiological research have established links between relevant human BPA exposure 
and diseases. In 2008, the first comprehensive environmental epidemiology study for 
 
10 
BPA reported significant positive associations between urinary BPA concentrations and 
risk for cardiovascular disease, type 2 diabetes, and liver enzyme abnormalities (Lang et 
al., 2008). Since then, a number of studies have correlated increased BPA exposure with 
adverse health outcomes across human populations that include increased sex hormone 
concentrations, decreased semen quality, altered childhood behavior, and recurrent 
miscarriages along with other metabolic and reproductive dysfunction (Braun et al., 
2011; Galloway et al., 2010; Meeker et al., 2010; Sugiura-Ogasawara, Ozaki, Sonta, 
Makino, & Suzumori, 2005; Laura N. Vandenberg, et al., 2013). While these findings do 
not imply causation and do not take into account co-exposures, results indicate that 
concentrations relevant to human exposures may be associated with both short-term and 
long-term disease outcomes.  
 
Bisphenol A mechanisms of action and toxicity 
BPA is a compound classically known for its weak estrogenic activity. As an 
EAC, BPA can perturb endocrine function by binding weakly to several steroid receptors 
including estrogen receptors (ER α and β), as well as thyroid and androgen hormone 
receptors (Gould et al., 1998; Kuiper et al., 1998; Moriyama et al., 2002; Welshons et al., 
2003).  In addition, BPA has a strong binding affinity for the trans-membrane ER, G 
protein-coupled receptor 30 (GPR30), and the orphan nuclear receptor, estrogen related 
receptor gamma (ERRγ) (Takayanagi et al., 2006; Thomas & Dong, 2006). BPA can also 
activate transcription factors, such as peroxisome x receptor (PXR) and the aryl 
hydrocarbon receptor (AhR), which are often involved in cross talk with steroid receptors 
(Kruger, Long, & Bonefeld-Jorgensen, 2008; Sui et al., 2012). Concentrations required 
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for receptor-mediated responses are tissue-dependent, given that receptor expression and 
occupancy differ from one cell type to another (Welshons, et al., 2003). 
As an EAC, BPA can also act through non-genomic signaling pathways. Unlike 
hormone receptor-mediated mechanisms, non-genomic systems can produce rapid, 
amplified responses after activation at low doses down to the pM-fM concentrations 
(Welshons, Nagel, & vom Saal, 2006).  In mammalian models, BPA can increase 
intracellular calcium influx as well as help modify different kinases and nuclear factors 
such as cAMP, MAPK, ERK, JNK, and NFkB (S. Lee et al., 2008; Song, Lee, & Choi, 
2002; Walsh, Dockery, & Doolan, 2005; Wozniak, Bulayeva, & Watson, 2005). The 
exact signal transduction mechanisms utilized by BPA are not well understood but are 
likely tissue-dependent.  
BPA’s mechanisms of action also include genomic toxicity and oxidative damage. 
In rats exposed to various concentrations of BPA, increased frequency of micronuclei, 
chromosomal aberrations, and DNA damage was observed in blood (Tiwari et al., 2012). 
Furthermore, DNA adducts as well as mitotic and meiotic aneuploidy were reported after 
exposure across several cell lines and animal models (De Flora et al., 2011; George et al., 
2008; Izzotti, Kanitz, D'Agostini, Camoirano, & De Flora, 2009; Johnson & Parry, 2008). 
In addition to genomic instability, several studies report that BPA induce reactive oxygen 
species and oxidative stress by altering mitochondrial function (Kabuto, Amakawa, & 




With crosstalk between cell membrane, cytosolic, nuclear, and genetic factors 
within the cell, EACs like BPA may act through several mechanisms simultaneously 
(Silva, Kabil, & Kortenkamp, 2010). Many of the receptors and factors play an important 
role in gene regulation important for normal differentiation and maturation processes, 
with implications for embryonic and fetal development. Thus, stimulation or inhibition of 
signaling pathways or damage to regulatory proteins in early development can produce a 
wide range of adverse cellular responses. The type of mechanism used and subsequent 
responses are dependent on BPA concentration, protein expression, cofactor availability, 
tissue location, and timing.  
 
Bisphenol A and epigenetic regulation 
There is evidence to suggest that epigenetic mechanisms aid in endocrine 
disruption. Alterations to the epigenome through changes in DNA methylation, histone 
modification, or non-coding RNAs help regulate gene activity without varying the DNA 
sequence.  Environmentally induced changes in expression and phenotype can occur 
through one or more stable modifications that persist throughout the lifetime (Wolffe & 
Matzke, 1999). These heritable markers are especially important for developmental gene 
regulation and can modify disease susceptibility; thus, epigenetic modifications are likely 
mechanisms that support the DOHaD hypothesis.  For example, EACs like 
diethylstilbestrol (DES) cause increases in breast cancer risk in adulthood as well as 
reproductive tract abnormalities several generations after initial exposure. These 
transgenerational effects from environmental estrogens are likely explained by epigenetic 
modifications to the germ line (Crews & McLachlan, 2006).  
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In several animal studies, developmental exposure to BPA caused 
hypermethylation of the estrogen receptor promoter regions in rat testis, hypomethylation 
of Hoxa10 in CD-1 mice reproductive tract, hypomethylation of the Pde4d4 gene in rat 
prostrate, and altered methylation of the A
vy
 gene in viable yellow agouti mice tails (O. 
Anderson et al., 2012; Bromer, Zhou, Taylor, Doherty, & Taylor, 2010; Doshi, Mehta, 
Dighe, Balasinor, & Vanage, 2011; S. Ho, W. Tang, J. Belmonte de Frausto, & G. Prins, 
2006). These DNA methylation changes were associated with decreased fertility, 
metabolic disorder, and prostate cancer. BPA also demonstrated increases in histone H3 
trimethylation and Enhancer of Zeste Homolog (EZH3) histone methyltransferase 
expression in mice mammary tissue (Doherty, Bromer, Zhou, Aldad, & Taylor, 2010). 
The newest studies in epigenetic research show that BPA is associated with alterations in 
several miRNAs including miR-146a in human placenta, mouse sertoli cell lines, and the 
ewe ovary (Avissar-Whiting et al., 2010; Cho et al., 2010; Nagel & Bromfield, 2013). 
Still, more studies are required that explore the interaction between multiple epigenetic 
pathways, especially in humans.  
 
 
1.4 Study Overview 
This dissertation research builds upon the theme of environmental exposures at 
vulnerable windows of development. Given its widespread presence and controversy, it is 
necessary to understand whether BPA poses a risk to environmental and community 
health. Without proper measurements of the true exposures and subsequent effects of 
BPA as well as other chemicals within our population, haphazard changes in policies and 
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social norms can be economically costly. On the other hand, confirmation of BPA related 
adverse health effects is essential to drive immediate regulatory changes or interventions. 
Even with the hundreds of BPA studies reported every year, this dissertation project 
contributes to the general body of literature, focusing on the most vulnerable of 
populations: the developing human fetus.  
BPA toxicology studies using animal models show strong evidence for an 
exposure-disease relationship, especially at low dose exposures with health effects related 
to developmental and reproductive dysfunction. Extrapolating these findings to humans is 
difficult given physiological and genetic differences from one species to another. Even 
after accounting for environmental exposures, how chemicals change within the body 
(toxicokinetics) and how the body responds to these chemicals (toxicodynamics) vary 
between species, across tissues, and with time (Dybing & Soderlund, 1999b). Human 
physiologically based pharmacokinetic (PBPK) models may be utilized, which 
mathematically simulate how chemicals are absorbed, distributed, metabolized, and 
excreted by relying on a priori knowledge of the human anatomical and biochemical 
makeup.  However, the robustness and reliability of these predictions are a major 
concern, and current PBPK models for a variety of chemicals have limited applications 
for the pediatric and obstetric community (Barrett, Della Casa Alberighi, Laer, & 
Meibohm, 2012). Environmental epidemiology studies are helpful for determining 
exposure-disease associations under real world conditions; however, expensive and time-
consuming longitudinal datasets are required to assess causality.  Thus, underlying 
mechanisms are often identified using in vitro or animal model systems. To properly 
understand exposure-disease relationships, it is ideal to characterize both the 
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toxicokinetic and toxicodynamic potential of a compound within humans. Accessibility 
of human target tissue for these analyses, while challenging, can be very informative for 
environmental health risk assessment. Acknowledging the limitations with traditional 
animal toxicological and epidemiological studies, this dissertation project bridges the 
knowledge gap by employing human clinical specimens to characterize different aspects 
of BPA toxicokinetics and toxicodynamics.  
A key factor in toxicological assessment is chemical biotransformation or 
xenobiotic metabolism. In the body, xenobiotic metabolism enzymes (XME) help 
activate or detoxify xenobiotics by altering the physiochemical properties of the 
compound within any given site. The chemical reactions are catalyzed by two groups of 
enzymes called phase I and phase II XMEs. Phase I XMEs catalyze hydrolysis, reduction, 
and oxidation reactions, while phase II XMEs are involved in glucuronidation, sulfation, 
acetylation, methylation, and other conjugation reactions (Casarett, Klaassen, & Watkins, 
2003). These chemical transformations increase hydrophilicity in order to assist in the 
elimination of foreign agents from the body. The enzymes are sensitive to the 
environment with expression or activity varying by cofactor and nutrient concentrations, 
genetic polymorphisms, age, tissue-type, and environmental exposures.  
 
Research objectives 
The overall goal for this project is to address different components of BPA 
toxicokinetic and toxicodynamic principles, specifically related to metabolism, which can 
be important for human development.  The three main chapters included in this 
dissertation focus on BPA exposure in tissue and the xenobiotic metabolism pathway 
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(Figure 1.2). In the first half of the dissertation, we identify differences in tissue-specific 
BPA concentrations as well as expression of BPA-specific XMEs in fetal versus adult 
livers (Aim 1, Chapter 2) or across various fetal tissues (Aim 2, Chapter 3). In the latter 
half, we explore BPA exposure-dependent changes in the expression of the general 
biotransformation system along with their epigenetic and genetic regulation (Aim 3, 
Chapter 4). While the dissertation project takes only a cross-sectional snapshot of a 
chemical across the developing human fetus in relation to xenobiotic metabolism, we 
investigate our scientific questions by using unique human clinical specimens and new 
high throughput technologies. These findings are relevant to human exposure and health 




In general, human studies are limited to surrogate tissues like saliva and blood to 
inform xenobiotic concentration or physiological changes related to a target tissue. To 
address our three specific aims in this dissertation, we utilized human fetal specimens.  
Pre-existing human fetal tissue samples, ranging from gestational day 70 to 120, were 
obtained from the NIH-funded University of Washington Laboratory for the Study of 
Human Embryology (LSHE) fetal tissue bank (2R24 HD000836-47). These healthy 
tissue specimens were originally collected from volunteers undergoing elective 




 trimester of pregnancy. After surgery and proper 
consent for donation, organs were flash-frozen and subsequently stored in polycarbonate-
free polypropylene tubing at -80 °C, prior to shipment to the University of Michigan 
 
17 
(UM) on dry ice.  Other than gestational age, and occasionally sex and race, no 
identifiable information regarding the clinical samples that could be traced to subjects 
was provided. Thus, samples met the criteria for IRB exemption for human subject 
research (UM IRB exemption: HUM00024929).  For Aim 1 and 3, we analyzed BPA 
concentrations and XME genes across N=50 fetal liver specimens. Of the 50 samples, 
N=12 fetal liver specimens were matched to fetal kidney and placental samples (N=12 
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CHAPTER 2  
In Utero Bisphenol A Concentration and Biotransformation Gene Expression 
Across Human Fetal and Adult Liver Specimens 
 
Text reused and modified from Nahar, M.S., Liao, C., Kannan, K., Dolinoy, D.C., 2013. 
Fetal Liver Bisphenol A Concentrations and Biotransformation Gene Expression Reveal 
Variable Exposure and Altered Capacity for Metabolism in Humans. J Biochem Mol 
Toxicol. 27(2):116-123. Permission for reuse approved by Rightslink and Copyright 




Widespread exposure to the endocrine active compound, bisphenol A (BPA), is 
well documented in humans.  A growing body of literature suggests adverse health 
outcomes associated with varying BPA concentrations. Here, we measured tissue 
concentrations of free BPA and conjugated BPA, and evaluated gene expression of 





 trimester human fetal liver samples. Both free BPA and conjugated BPA 
concentrations varied widely, with free BPA exhibiting three times higher concentrations 
than conjugated BPA concentrations. As compared to gender-matched adult liver 
controls, UDP-glucuronosyltransferase (UGT2B15), sulfotransferase (SULT1A1), and 
steroid sulfatase (STS) genes exhibited reduced expression while β-glucuronidase 
(GUSB) mRNA expression remained unchanged in the fetal tissues.  This study provides 
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evidence that there is considerable exposure to BPA during human pregnancy and that 




Human exposure to BPA is widespread, and several studies have reported 
detectable concentrations of total urinary BPA in a majority of individuals in populations 
around the world, including the United States, China, and Korea (Calafat, Ye, Wong, 
Reidy, & Needham, 2008; Z. Zhang et al., 2011). Since the first BPA biomonitoring 
study conducted at the U.S. Centers for Disease Control and Prevention (CDC) in 2001, 
dozens of spot or pooled urine specimens have been examined across different cohorts 
for BPA, accounting for exposure from a variety of sources (Brock et al., 2001). 
Detectable urinary BPA concentrations have been observed across various age groups; 
the body burden generally decreases with age, indicating higher BPA concentrations in 
children compared to adults (Calafat, et al., 2008). Although most human biomonitoring 
studies report total BPA concentrations in urine, the different individual BPA species are 
typically unspecified and concentrations do not reflect the absorbed or internal dose.   
In the BPA scientific community, there is a consensus for proper sampling and 
improved technical analysis. Recent studies have addressed BPA internal dose by 
measuring circulating concentrations in serum, plasma, and cord blood (He et al., 2009; 
Kaddar et al., 2009; Volkel, Bittner, & Dekant, 2005; M. Yang, Ryu, Jeon, Kang, & Yoo, 
2009). Furthermore, techniques that account for contamination and detect BPA at lower 
concentrations are becoming popular, although remain limited by high costs. Studies that 
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specifically report the internal dose of BPA in tissue are scarce.  Access to tissue is often 
difficult and optimizing analyses for this matrix prove to be tricky. Still, quantifying 
tissue BPA concentrations, especially in humans, is necessary for better risk assessment 
and determination of BPA associated adverse health outcomes. 
While the debate on human BPA exposure-disease relationships continues, the 
National Toxicology Program (NTP) declared in 2008 that there is concern for BPA 
toxicity in sensitive populations such as pregnant women, fetuses, and children. So far, 
BPA has been reported in pregnancy-related biological fluids, including breast milk, 
amniotic fluid, and follicular fluid (Edlow, Chen, Smith, Lu, & McElrath, 2012; Engel, 
Levy, Liu, Kaplan, & Wolff, 2006; Ikezuki, Tsutsumi, Takai, Kamei, & Taketani, 2002; 
Sun et al., 2004; Yamada et al., 2002; Ye, Kuklenyik, Needham, & Calafat, 2006).  In 
adults, human pharmacokinetic data suggest rapid metabolism of estrogenic free BPA 
into the non-estrogenic BPA-glucuronide and BPA-sulfate conjugates, via UDP-
glucuronosyltransferase (UGT2B15) and sulfotransferase (SULT1A1) enzymes, followed 
by urinary elimination (Hanioka, Naito, & Narimatsu, 2008; Nishiyama et al., 2002).  In 
human and rodent fetuses and neonates, however, there is generally reduced or altered 
capacity for chemical detoxification (Hines & McCarver, 2002; McCarver & Hines, 
2002); thus, metabolism may not ensure negligible risk in these vulnerable populations. 
Furthermore, β-glucuronidase (GUSB) and steroid sulfatase (STS), enzymes that catalyze 
the breakdown of inactive BPA conjugates to free BPA, have been detected in 
mammalian placenta (Kriz, Bicikova, & Hampl, 2008; Sperker, Backman, & Kroemer, 
1997).  Studies report detectable concentrations of estrogenic free BPA in the human 
placenta and amniotic fluid, indicating the potential for dysregulation of important 
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biological processes necessary for fetal development and disease progression later in life 
(Cao et al., 2012; Ikezuki, et al., 2002; Jimenez-Diaz et al., 2010).  




 trimester human liver specimens were 
analyzed using a high performance liquid chromatography based technique for 
endogenous BPA concentrations to assess in utero exposure.  In order to assess the ability 
of the fetus to detoxify BPA, tissue-specific BPA concentrations were compared to 
expression of metabolizing enzyme isoforms specific for BPA biotransformation. In this 
chapter, the primary objective was to compare BPA concentrations and mRNA 
expression between fetal and adult liver specimens in order to test the hypothesis that the 
developing fetus is at a greater risk for BPA exposure and subsequently, BPA toxicity.   
 
 
2.3 Materials and Methods 
Tissue samples 
From the fetal tissue biobank, N=50 fetal liver specimens weighing more than 700 
mg were chosen. With the exception of one sample, all flash frozen fetal livers were 
stored at -80°C for less than 2 years with more than 75% of samples stored for less than 1 
year.  Furthermore, multiple tissue freeze-thaw events were minimized to prevent BPA 
and mRNA degradation. Previously, BPA in urine samples stored at -20°C over a year 
exhibited minimum degradation (Calafat et al., 2005), and thus is not expected to be a 
considerable limitation in our study.  No significant correlation was observed between 
time in -80°C storage and free BPA concentrations (r <0.03). While tissue type and 
gestational age was available for all specimens, several samples had missing sex 
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information (N=10).  Sex was determined from these particular tissues by assaying for 
the Y chromosome-specific SRY and the X chromosome-specific ATL1 genes using a 
nested PCR analysis as described previously, with slight modifications (Tungwiwat, 
Fucharoen, Ratanasiri, Sanchaisuriya, & Fucharoen, 2003).   
As controls, healthy frozen adult liver samples were procured (Asterand, Detroit, 
MI). These normal adult liver specimens, belonging to one male and one female 50-year-
old Caucasian subjects, were recovered from routine autopsies, stored in polycarbonate-
free polypropylene tubing, and immediately flash frozen for storage. The liver specimens 
did not exhibit any pathological characteristics.  
 
BPA analysis and quality control  
Frozen liver samples were processed for quantification of free BPA and 
conjugated BPA species.  An average of 630 mg (between 400-970 mg) of excised frozen 
tissue was pulverized into fine powder using a stainless steel mortar and ceramic pestle 
above liquid nitrogen and stored in a 2 mL polypropylene eppendorf tube. The 
homogenized tissue was shipped to the Wadsworth Center (New York State Department 
of Health, Albany, NY) overnight on dry ice, where samples were processed.  
Homogenized liver samples were spiked with 5 ng of the internal standard, 
13
C12-BPA, 
and further homogenized in 5 mL of acetonitrile. The method for the analysis of free 
BPA and conjugated BPA has been previously described (O. S. Anderson et al., 2012). 
Briefly, tissue samples were extracted several times with acetonitrile, and reconstituted 
with 10% dichloromethane in hexane. Sample extract was then loaded onto a Strata NH2 
cartridge (200mg/3cc, Phenomenex, Torrance, CA) pre-conditioned with 5 mL of 80% 
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methanol in acetone and 5 mL of hexane. The cartridge was washed with 5 mL of hexane 
and eluted with 5 mL of 80% methanol in acetone. The eluate was concentrated to 0.5 
mL under a gentle stream of nitrogen.  The resulting extract represents free BPA, while 
the residual pellet was further processed for conjugated BPA quantification.  The pellet, 
after addition of 5 ng of the internal standard and 1 mL of water, was digested in 1 mL of 
1 M ammonium acetate buffer containing 2 μL/mL β-glucuronidase (with 0.6% sulfatase 
activity; from Helix pomatia, 145700 unit/mL, Sigma, St Louis, MO) at 37ºC for 12 hrs.  
This conjugated BPA fraction was extracted thrice with ethyl acetate. The sample extract 
was concentrated to near dryness, reconstituted with 10% dichloromethane in hexane, 
and purified by passing through a Strata NH2 cartridge as described above. The final 
eluate was concentrated to 0.5 mL. 
BPA and 
13
C12-BPA detection from both extracts were quantified using a high-
performance liquid chromatography (HPLC) coupled with API 2000 electrospray triple-
quadrupole mass spectrometer (ESI-MS/MS; Applied Biosystems, Foster City, CA), and 
modified from a protocol published previously (Padmanabhan et al., 2008).  Ten µL of 
each extract was injected onto an analytical column, set at 25°C and a flow rate of 300 
µL/min with the mobile phase comprised of varying methanol and water mixtures (25-
99% methanol gradient).  Instrument parameters were as follows: MS/MS was set to 
electrospray negative mode, cone voltage set at -30 V, collision energy set at -25 V, 
capillary voltage set at -4.5 KV, and desolvation temperature set at 400°C. For detection, 
transitions were monitored at 227>212 for BPA and 239>224 for 
13
C12-BPA using 
multiple reaction monitoring (MRM).  
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Several quality assurance and quality control measurements were taken to assure 
the validity of the analytical technique. Selected sample matrices were spiked with BPA 
standards and then passed through the entire analytical procedure. Results indicated an 
average recovery of 104% (90-120%) for spiked BPA and 85% (65-120%) for spiked 
13
C12-BPA.  An external calibration curve was prepared by injecting standards at varying 
concentrations (10 µL of 0.05-100 ng/mL), resulting in a calibration coefficient >0.99. In 
addition, a procedural blank (water) was analyzed between every 10 samples that were 
analyzed. To prevent contamination, only polypropylene or BPA-free supplies were used 
during sample processing. Furthermore, BPA-free water was stored at -80°C and then 
pulverized over the frozen mortar and pestle apparatus, similar to the process described 
above, to assess contamination introduced during homogenization. Free BPA and 
conjugated BPA concentrations were both below the limit of quantification (LOQ) of 0.1 
ng/g in controls and blanks. For data analysis, liver BPA concentrations below the LOQ 
were assigned a value of 0.071 ng/g, which was estimated by dividing the LOQ by the 
square root of 2.  
 
RNA extraction and cDNA synthesis 
Total RNA, in addition to genomic DNA and total protein, was purified from 
frozen liver tissue using the AllPrep DNA/RNA/Protein kit (Qiagen, Valencia, CA) 
according to the manufacturer’s instructions. Before extraction, 10-20 mg of tissue was 
added to a 2 mL round bottom micro-centrifuge tube containing 600 µL of Buffer RLT 
with 1% β-mercaptoethanol and a 5 mm stainless steel bead, and subsequently 
homogenized twice for 2 min at 20 Hz in the TissueLyser II (Qiagen). RNA quality and 
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quantity was assessed using the Nanodrop 2000 spectrophotometer (Thermo Scientific, 
Wilmington, DE) and Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA).   
To generate complementary DNA for each sample, approximately 1 µg of total 
RNA template was used with the iScript cDNA synthesis Kit (Bio-Rad, Hercules, CA) 
following the manufacturer’s protocol.  The thermocycler settings for cDNA synthesis 
required incubation at 25°C for 5 min, 42°C for 60 min, and 90°C for 5 min.  
 
Primer design and real-time quantitative PCR 
Primer pairs for real time quantitative polymerase chain reaction (RT-qPCR) were 
designed for four genes related to BPA metabolism using GenScript Real Time PCR 
(TaqMan) Primer Design Tool (GenScript, Piscataway, NJ). The final UGT2B15 primer 
sequence was obtained from the Harvard Primer Bank. The primers for human liver 
reference genes, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), Ubiquitin C 
(UBC), and β2-microglobulin (B2M), were similarly designed using GenScript. All RT-
qPCR primers (Table 2.1) were verified using Primer BLAST 
(www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi?LINK_LOC=BlastHome) and 
chosen avoiding sequence alignment over polymorphisms or multiple binding sites. Most 
primers span introns or bridge exon-exon junctions, resulting in unique amplicons 50-200 
base pairs long. All primer sets were tested for PCR efficiency using 10-fold serial 
dilutions of a standard template. Primers with the best standard curve slope and R
2
 values 
(>0.97) were chosen as the final RT-qPCR assay.   
Template amplification was set up in a 25 µL reaction for RT-qPCR using the iQ 
SYBR Green Supermix (Bio-Rad, Hercules, CA). Each reaction, containing 2 µL of 10-
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fold diluted cDNA template and 100 nM primer concentration, was carried out in 
triplicate on a C100 Thermal Cycler with a CFX96 Real-Time head (Bio-Rad). Each 96-
well plate contained No Template Controls (NTC) for individual primer sets as well as 
Plate Control (PC) samples to adjust for inter-plate variability.  RT-qPCR cycle 
parameters were set to 95°C for 3 min, and 40 cycles of 95°C for 10 sec and 55°C for 30 
sec, followed by 95°C for 10 sec and 65°C for 5 sec.   
The average threshold cycle (CT) from triplicate runs was calculated for 
individual genes using the CFX Manager Version 1.6 software (Bio-Rad). An inter-run 
calibration using the plate controls automatically adjusted data points between plates. For 
normalized expression, the software takes the CT for each gene and then normalizes the 
values to the average CT of the endogenous reference genes: GAPDH, UBC, and B2M.   
Results are reported as normalized fold expression change (2
−ΔΔCT
) with standard error of 
the mean. The normalized fold change value reported herein represents fetal expression 
relative to expression in a gender matched adult control, where fold change equals one.  
 
Statistical analysis 
Distribution of BPA in liver tissue was examined and did not appear to be normal. 
Free BPA, conjugated BPA, and total BPA (ng/g wet weight) concentrations were 
presented as percentiles and geometric means. Bivariate nonparametric tests (Wilcoxon 
rank sum and Spearman correlation) were used to analyze free BPA and conjugated BPA 
concentrations with covariates such as sex and gestational age.  Similar bivariate analyses 
were conducted separately with the primary predictors: mRNA expression of UGT2B15, 
GUSB, SULT1A1, and STS. Simple and multiple linear regression models, in which BPA 
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concentration outcomes were log transformed, were tested to assess the relationship 
between BPA tissue concentrations and gene expression.  Each of the four genes were 
individually analyzed with free BPA, and separately with free to conjugated BPA ratio, in 
a simple linear regression model. Regression models were not analyzed for conjugated 
BPA species given that the exact BPA-glucuronide and BPA-sulfate conjugate 
composition was unknown. In the multiple linear regression models, gene expression and 
free BPA or free: conjugated BPA ratio were analyzed after adjusting for gestational age, 
as a confounder, and sex, as an effect modifier.  Regression coefficients (β) were 
analyzed and calculated as percent change [100(e^β -1)] with p-values <0.05 representing 
statistical significance. All statistical analyses were conducted using the stats and epicalc 




BPA concentrations in liver 
In the adult liver controls, the concentrations of conjugated BPA were both below 
the limit of quantification (<LOQ), while the concentrations of free BPA were <LOQ and 
0.38 ng/g (Table 2.2). Greater than 70% of the 50 fetal liver samples, however, contained 
detectable concentrations of free BPA and conjugated BPA, ranging from <LOQ to 50.5 
ng/g (geometric mean: 2.26 ng/g) and <LOQ to 49.5 ng/g (geometric mean: 0.65 ng/g), 
respectively (Table 2.2 & Table 2.3).  The majority (78%) of samples exhibited a free 
BPA to conjugated BPA ratio greater than 1, with a mean of 6.91 and median of 3.75, 
across all gestational age and sex (Table 2.2). No significant differences in free BPA (p-
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value: 0.675) or conjugated BPA (p-value: 0.976) concentrations were observed between 
male and female specimens. After assessing BPA concentrations over developmental 
time span (Figure 2.1), gestational age was found to be significantly correlated with free 
BPA (r=0.316; p-value: 0.025) but only marginally significant with conjugated BPA 
(r=0.267; p-value: 0.059) across all samples.  In a meta-analysis of free BPA across adult 
tissues, pregnancy related biological fluids, and pregnancy related tissues from published 
studies (Figure 2.2), concentrations in our adult and fetal liver specimens were 
comparable to similar cohorts that use various analytical techniques. 
 
BPA-specific XME gene expression in liver  
In general, mRNA expression of UGT2B15 and SULT1A1 was significantly 
reduced (p-values: 0.039 and 0.044, respectively), while STS expression was marginally 
reduced (p-value: 0.054) in fetal liver compared to adult liver samples.  Furthermore, 
normalized mRNA expression was significantly higher in male compared to female fetal 
livers, especially for UGT2B15, SULT1A1, and STS expression (p-values <0.005; Figure 
2.3). GUSB displayed no significant difference in expression between fetal and adult liver 
samples (p-value: 0.197). There were no significant correlations between expression of 
the four BPA biotransformation genes and gestational age (p-values >0.200).  
 
BPA concentration and XME gene expression associations in liver 
The association between free BPA concentrations and expression of BPA-specific 
XME genes in fetal liver was assessed using linear regression. No significant associations 
were observed between free BPA concentrations and expression levels in simple 
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regression modeling (UGT2B15 p-value: 0.441, SULT1A1 p-value: 0.914, GUSB p-value: 
0.477, and STS p-value: 0.753). The correlation between free BPA and many of the gene 
expression profiles, however, differed between male and female liver specimens, 
suggesting that sex may act as a potential effect modifier. Therefore, in the final model, 
an interaction term between sex and expression was added along with adjustment for 
gestational age. There were no significant relationships between free BPA tissue 
concentration and individual biotransformation gene expression values adjusting for 
gestational age, sex, and their interaction (p-values >0.500).  Actual maternal BPA 
exposures are likely to differ from one study subject to another; thus, free to conjugated 
BPA ratio may be a better metric for understanding metabolism capacity. We conducted a 
similar analysis between free: conjugated BPA and the gene expression profiles. For both 
simple linear and adjusted regression models, no significant associations were reported 
between free: conjugated ratio and mRNA expression (UGT2B15 p-value >0.767, 




Studies reporting internal dose of BPA in human tissue at vulnerable 
developmental stages are presently lacking. When we measured endogenous BPA 
concentrations in human fetal liver, more than 70% of samples exhibited detectable 
concentrations of free and conjugated species, ranging from <LOQ to 50 ng/g (or parts 
per billion). Comparable concentrations of free BPA in pregnancy related tissue have 
been previously reported in 49 term placentas collected from Spanish women (<LOQ- 
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22.2 ng/g), 248 amniotic fluids from 2
nd
 trimester Japanese women (<LOQ-5.62 ng/mL), 
and 28 fetal livers from a Canadian population (<LOQ-37.7 ng/g) (Cao, et al., 2012; 
Jimenez-Diaz, et al., 2010; Yamada, et al., 2002).  Often, these studies only quantify free 
BPA or total BPA, and the LOQs are higher than 0.1 ng/g.  Still, the exposure distribution 
profiles of our samples were equivalent to other cohorts that used different analytical 
techniques as seen in Figure 2.2. 
A higher free BPA to conjugated BPA ratio in this sample population is especially 
notable, given that free BPA normally represents 10-30% of total BPA in adult urinary 
excretions (Koch, Kolossa-Gehring, Schroter-Kermani, Angerer, & Bruning, 2012; Liao 
& Kannan, 2012). The discrepancy in our clinical samples may be attributed to varying 
metabolic potential across biomonitoring samples and time points. For example, given 
the nature of BPA metabolism and excretion in adults, limited concentration of free BPA 
in circulating blood and a high percentage of conjugated species in urine specimen are 
expected. Contrary to this initial model, free BPA has been detected in blood 
measurements across various studies and these inconsistencies have brought to light the 
issue of BPA contamination during sample processing and analysis (L. N. Vandenberg et 
al., 2012a).  In this study, several experimental precautions were taken, including use of 
polycarbonate-free equipment and negative controls throughout processing. Any 
exogenous BPA introduced during tissue procurement likely affected all samples; 
however, the wide range of free BPA and <LOQ concentrations observed implies 
otherwise. Toxicokinetic differences in the fetal versus adult organism may be a probable 
explanation for the observance of high free to conjugated ratio in our clinical samples. In 




 trimester amniotic fluid from American women 
 
40 
found that free BPA accounted for more than 80% of total BPA concentrations (Edlow, et 
al., 2012).  Furthermore, a study measuring BPA in midgestational umbilical cord serum 
determined that on average BPA-glucuronide make up 19% and free BPA make up 36% 
of total BPA in the sample population (Gerona et al., 2013). While significant differences 
in structure and function between animal species make it hard to extrapolate to humans, 
one study in rats reported a decrease in % free BPA in tissue with increasing age after iv 
administration, consistent with age related increases in Phase II conjugation (Doerge, 
Twaddle, Vanlandingham, Brown, & Fisher, 2011). 
 The biotransformation system undergoes significant changes during hepatic 
maturation, resulting in differential response to xenobiotic chemicals. Hepatic mRNA and 
protein expression of 13 UGT genes, including UGT2B15, were not detectable in the 
fetus and were reduced in children compared to adults (Strassburg et al., 2002).  In our 
larger collection of samples, we also found significantly reduced mRNA expression of 
UGT2B15 in fetal liver. While fetal GUSB did not show differential expression, STS 
exhibited significantly reduced expression compared to adult livers, as supported by other 
studies (Collier, Tingle, Paxton, Mitchell, & Keelan, 2002; Lucier, Sonawane, & 
McDaniel, 1977; Miki et al., 2002). Hepatic SULT genes, especially SULT1A1, often 
exhibit protein expression levels that are equivalent to adult levels (Duanmu et al., 2006; 
Stanley, Hume, & Coughtrie, 2005). Although we observed reduced mRNA expression 
of SULT1A1 in fetal liver, there was wide variability in our samples. Future studies can 
be improved by increasing the number of adult liver controls to account for inter-subject 
variability resulting from not only differential exposure but also genetic variation 
contributing to altered xenobiotic metabolism.  Furthermore, integration of gene 
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ontogeny with genetic variants involved in differential BPA metabolism, such as the 
UGT2B15 D85Y substitution (Hanioka, Oka, Nagaoka, Ikushiro, & Narimatsu, 2011), 
among others, will be necessary for complete understanding of altered BPA metabolism 
in human fetal samples.   
When the relationship between biotransformation gene expression and free BPA 
concentration was examined, no significant correlations were observed. Important 
epidemiological information for individual clinical specimen was unavailable for this 
study. Access to certain maternal data may have shed light on true maternal BPA 
exposures and other co-exposures throughout pregnancy. Therefore, to account for 
differences attributed to initial maternal exposures, we also examined correlations using 
the free to conjugated BPA ratio but did not find any significant associations.  In addition 
to small sample size, several reasons may help explain the lack of association, even after 





 trimester liver samples may not be a good proxy for measuring functional activity 
of biotransformation enzymes at this particular window of development. Thus, 
experiments that assess protein activity of BPA biotransformation enzymes in fresh 
human tissue will be valuable. For proper metabolism, enzyme reactions are also limited 
by tissue cofactor concentrations and nutrient availability (Bidlack, Brown, & Mohan, 
1986); low levels of cofactors such as 3’-phophoadenosine 5’-phosphosulfate (PAPS) and 
UDP-glucuronic acid may limit BPA conjugate production even with optimal protein 
expression.  Second, there is also the possibility that, despite experimental precautions 
described above, free BPA was introduced exogenously during sample procurement, and 
this contamination may have negated any true associations between expression and 
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exposure. Therefore, the optimal regression model should evaluate biotransformation 
gene expression with their respective BPA species (i.e. SULT1A1 with BPA-sulfate only, 
UGT2B15 with BPA-glucuronide only). Future analyses will require separate 
characterization of both BPA-glucuronide and BPA-sulfate in tissue. Finally, the high 
free BPA to conjugated BPA ratio observed may also be a result of deconjugation in the 
placenta or differential biotransformation from physiological changes occurring in the 
mother during pregnancy (Abduljalil, Furness, Johnson, Rostami-Hodjegan, & Soltani, 
2012; Lucier, et al., 1977). To assess BPA fate throughout human pregnancy, 
investigation of BPA metabolism and transport in the placenta, maternal liver, and across 
other fetal compartments is required.  Thus, in a subsequent chapter, we address BPA 
concentration and metabolism across matched tissues from individual subjects.  
As is true in many human studies, bioethical issues and the paucity of appropriate 
samples limit our ability to comprehend the role of BPA biotransformation during this 
sensitive window of development. This study is one of the first of its kind to investigate 
both BPA conjugating and deconjugating enzyme gene expression in relation to 
endogenous BPA exposure in the developing human fetus. Characterizing 
biotransformation gene ontogeny with BPA exposure from early gestation to birth will 







Table 2.1 RT-qPCR Primers for BPA XME Analysis 
Gene Type Gene Full Name 
GenBank 









Forward CCAACCAATGAAGCCCCTG 60.7 
94 
Reverse GTTGTGAGCTGCGACTCGAA 62.7 
Conjugation SULT1A1 Sulfotransferase NM_001055 
Forward TCAAGGTGGTCTATGTTGCC 58.6 
149 
Reverse CCAGGATCCGTAGGACACTT 59.0 
Deconjugation STS Steroid Sulfatase NM_000351 
Forward AGCACTGATAGGGAAATGGC 59.2 
82 
Reverse GAAGCCGTGATGTAAAGGGT 59.1 
Deconjugation GUSB B-Glucuronidase NM_000181 
Forward ATCGCCATCAACAACACACT 59.0 
82 






Forward CATCAATGGAAATCCCATCA 59.1 
90 
Reverse GACTCCACGACGTACTCAGC 58.5 
Reference UBC Ubiquitin C NM_021009 
Forward GATCGCTGTGATCGTCACTT 58.8 
112 
Reverse TCTTTGCCTTGACATTCTCG 59.0 
Reference B2M β2-microglobulin NM_004048 
Forward TCGCTCCGTGGCCTTAGCTG 58.9 
161 
Reverse CAATGTCGGATGGATGAAACCCAG 56.1 





Table 2.2 BPA Concentrations in Liver Specimen 







Adult Liver 1 50 Y M 0.38 <LOQ 5.30 
Adult Liver 2 50 Y F <LOQ <LOQ 1.00 
Fetal Liver 1 GD 101 M 47.23 49.54 0.95 
Fetal Liver 2 GD 110 F 31.24 7.01 4.46 
Fetal Liver 3 GD 91 F 25.54 9.90 2.58 
Fetal Liver 4 GD 98 F 31.25 7.78 4.01 
Fetal Liver 5 GD 103 F 16.91 4.22 4.00 
Fetal Liver 6 GD 105 M 11.77 4.33 2.72 
Fetal Liver 7 GD 107 M 3.63 0.61 5.94 
Fetal Liver 8 GD 110 F 3.93 0.59 6.70 
Fetal Liver 9 GD 115 M 40.22 15.85 2.54 
Fetal Liver 10 GD 101 F 12.05 13.03 0.92 
Fetal Liver 11 GD 98 F 3.49 2.29 1.52 
Fetal Liver 12 GD 86 F 1.68 1.18 1.42 
Fetal Liver 13 GD 89 F 12.47 1.05 11.93 
Fetal Liver 14 GD 93 F 16.47 3.99 4.13 
Fetal Liver 15 GD 94 M 3.68 0.47 7.79 
Fetal Liver 16 GD 96 M 1.81 0.29 6.24 
Fetal Liver 17 GD 108 M 12.98 4.67 2.78 
Fetal Liver 18 GD 113 M 3.45 0.40 8.52 
Fetal Liver 19 GD 114 F 2.12 0.81 2.60 
Fetal Liver 20 GD 120 M 2.71 0.68 3.99 
Fetal Liver 21 GD 96 M 1.71 0.45 3.81 
Fetal Liver 22 GD 108 F 2.00 0.50 3.98 
Fetal Liver 23 GD 105 M 50.50 3.23 15.63 
Fetal Liver 24 GD 115 M 4.69 0.87 5.41 
Fetal Liver 25 GD 101 F 3.76 1.02 3.69 
Fetal Liver 26 GD 96 M 0.54 0.66 0.82 
Fetal Liver 27 GD 101 F 1.55 0.50 3.11 
Fetal Liver 28 GD 105 M 0.66 0.65 1.01 
Fetal Liver 29 GD 91 M 4.77 22.70 0.21 
Fetal Liver 30 GD 98 F 0.78 <LOQ 11.09 
Fetal Liver 31 GD 101 M 1.82 1.28 1.42 
Fetal Liver 32 GD 96 F 1.18 <LOQ 16.69 
Fetal Liver 33 GD 94 M 5.90 0.48 12.34 
Fetal Liver 34 GD 94 M 1.80 0.65 2.76 
Fetal Liver 35 GD 96 F 3.27 0.22 14.60 
Fetal Liver 36 GD 96 F 0.83 <LOQ 11.71 
Fetal Liver 37 GD 89 M <LOQ <LOQ 1.00 
Fetal Liver 38 GD 98 F 0.32 0.42 0.75 
Fetal Liver 39 GD 105 M <LOQ <LOQ 1.00 
Fetal Liver 40 GD 113 M <LOQ <LOQ 1.00 
Fetal Liver 41 GD 80 F 0.16 <LOQ 2.23 
Fetal Liver 42 GD 98 M 4.52 <LOQ 63.93 
Fetal Liver 43 GD 104 M 6.63 1.28 5.18 
Fetal Liver 44 GD 74 M 0.43 <LOQ 6.11 
Fetal Liver 45 GD 94 F 1.12 <LOQ 15.84 
Fetal Liver 46 GD 82 F <LOQ <LOQ 1.00 
Fetal Liver 47 GD 85 M <LOQ <LOQ 1.00 
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Fetal Liver 48 GD 95 M <LOQ <LOQ 1.00 
Fetal Liver 49 GD 113 F 3.50 <LOQ 49.50 
Fetal Liver 51 GD 103 M 1.19 0.70 1.70 






Table 2.3 Distribution of Free, Conjugated, and Total BPA (ng/g) in Human Fetal Liver 
Tissues (Gestational Age: day 74-120, N=50)  
BPA Species  
 Above LOQ
a












Free  88 <LOQ <LOQ 0.90 2.99 6.45 26.1 50.5 
Conjugated  72 <LOQ <LOQ <LOQ 0.63 2.04 8.00 49.5 
Total   <LOQ <LOQ 1.18 3.44 12.1 35.7 96.8 
aLOQ = 0.1 ng/g 




Figure 2.1 Scatter Plot Displaying the Association Between Gestational Age and BPA 
Concentration 
 
(A) A significant positive correlation between free BPA concentration and gestational age is observed 
(overall r: 0.316, p-value: 0.025). When the exposure-age correlation was stratified by sex, no significant 
differences were observed (female r: 0.333, p-value: 0.120; male r: 0.345, p-value: 0.078). (B) A 
marginally significant trend was found between conjugated BPA and gestational age (overall r: 0.269 and 












Figure 2.2 Meta-Analysis of Free BPA Across Different Human Specimen 
 
The forest plot displays the distribution of free BPA reported across all published studies addressing BPA internal dose in humans.  Each line indicates 
the minimum and maximum with the dot indicative of the average BPA concentration. Several studies did not report the mean, so the median (y) or 
geometric mean (z) was reported instead. Red dots represent studies reporting free BPA quantified in adult tissue, green dots represent studies that 
quantified free BPA in pregnancy related biological fluids like cord blood and amniotic fluid, and blue dots represent those in pregnancy related tissue 
specimen. As indicated by the plot, our study is the first to quantify free BPA in adult and pregnancy related tissue in the USA, with considerable 





Figure 2.3 Boxplots Representing Relative Expression of BPA-specific XMEs in Fetal 
Liver 
 
Boxplots represent sex stratified biotransformation enzyme expression in fetal livers compared to adult 
livers, normalized to 1 fold change for each gene. (A) Fetal liver expression of UGT2B15 is significantly 
reduced compared to adults (overall p-value: 0.039). Here, normalized male expression is significantly 
higher than female expression (p-value <0.001). GUSB, however, does not exhibit significant difference in 
expression between fetal and adult samples (overall p-value: 0.197).  Also, there is no significant difference 
in normalized expression between male and female (p-value: 0.463). (B) Fetal liver expression of SULT1A1 
is also significantly reduced compared to adults (overall p-value: 0.044). The difference in STS expression 
between fetal compared to adult samples is only marginally significant (overall p-value: 0.054). 
Normalized male expression is significantly higher than female expression in both SULT1A1 and STS (p-
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CHAPTER 3  
In Utero Bisphenol A Concentration, Biotransformation, and Global DNA 
Methylation Across Matched Placenta, Kidney, and Liver in the Human Fetus 
   
 
3.1 Abstract 
 While urine has been an easily accessible and feasible matrix for human 
biomonitoring, accurate environmental exposure and epidemiology assessments require 
internal dose measurements using blood and tissue to properly determine disease 
etiology.  This is especially important for the endocrine active compound, bisphenol A 
(BPA), where studies investigating internal dose at sensitive periods of human 
development are currently lacking. For this project, we quantified BPA concentrations 





 trimester human subjects (N=12).  The metabolically active placenta, 
fetal liver, and fetal kidney specimens were also analyzed for exposure-dependent 
alterations in global DNA methylation in order to characterize BPA’s early regulatory 
effects. Compared to fetal liver, BPA concentrations were lower in matched placenta and 
kidney specimens. BPA-specific metabolism gene expression levels differed across each 
tissue type; however, conjugation and deconjugation patterns were similar across the 
fetus. In general, the expression of GUSB and SULT1A1 was higher than the respective 
UGT2B15 and STS genes, indicating that BPA-glucuronide deconjugation and BPA 
sulfation reactions are likely to predominate in the early fetus.  Tissue-specific DNA 
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methylation differences in global repetitive content, as measured by LINE1 (p-value 
<0.001) and global CCGG content, as measured by LUMA (p-value <0.001) were 
observed.  Average LINE1 and CCGG global methylation were 58.27 and 59.15% in 
placenta, 79.49 and 66.42% in fetal liver, and 77.92 and 76.99% in fetal kidney. Total 
BPA concentrations were significantly associated with global methylation only for 
placenta using the LINE1 assay (p-value: 0.002), suggesting organ-specific biological 
effects after fetal exposure. This study takes advantage of human clinical specimens to 
assess BPA biomonitoring, toxicokinetics, and toxicodynamics within matched tissues 
across individuals. Findings are novel and provide evidence for BPA body burden and 




 Characterizing internal dose, defined as the absorbed concentration, is essential 
for accurately detecting associations between exposures and adverse health outcomes. 
Therefore, biomonitoring focus has recently shifted from urinary measurements to 
quantification of xenobiotics in circulating blood and tissue, especially for human 
bisphenol A (BPA) studies. Urine measurements may be sufficient for understanding 
general BPA exposure given its short half-life in adults (Volkel, et al., 2002), but tissue 
measurements provide evidence for contact at target sites with implications for organ-
specific biological effects.  Continuous exposure to even minute amounts of BPA may 
cause the rate of absorption to exceed the rate of elimination, resulting in accumulation. 
Bioaccumulation and lipophilic properties have been previously suggested for BPA. One 
 
55 
human in vitro study noted a high fat: blood partition coefficient for BPA (Csanady et al., 
2002), and in a later study BPA was detected in adipose tissue collected from Spanish 
women (Fernandez et al., 2007). Thus far, there are only a handful of studies reporting 
BPA concentration in tissue because human tissue acquisition is difficult and analytical 
techniques still require optimization in these complex matrices.   
 Information regarding human BPA internal dose is currently limited to studies 
quantifying the compound in biological fluids like blood, saliva, and breast milk or 
estimated from physiologically based pharmacokinetic (PBPK) models (L. N. 
Vandenberg, et al., 2012a). There is often conflict between biomonitoring data and these 
PBPK models, leading to considerable debate in the BPA community (L. N. Vandenberg, 
Hunt, Myers, & Vom Saal, 2013). For example, under the assumption that BPA is 
completely metabolized to its conjugates and rapidly excreted via urine, BPA is expected 
to be undetected in blood, yet several studies have reported detectable BPA 
concentrations in circulation (Kaddar, et al., 2009; Y. J. Lee et al., 2008; Padmanabhan, 
et al., 2008).  Discrepancies exist because our understanding of human BPA 
toxicokinetics is inconclusive, especially across different age groups.  
 Comprehensive BPA toxicokinetic studies have been established using animal 
models, and are sometimes inappropriately extrapolated to humans. In a study comparing 
BPA clearance rates after 400 µg/kg/day oral dose of deuterated-BPA in rhesus macaques 
and female CD1 mice, researchers noted similar serum BPA profiles over time with a 
peak concentration 1 hr after initial exposure (Taylor et al., 2011). The estimated kinetic 
parameters were similar across mice, monkeys, and humans, with findings suggestive of 
considerable exposure through non-oral routes and incomplete first-pass metabolism. 
 
56 
More recently, studies have addressed high BPA exposure and risk concerns in pregnant 
animal populations.  After subcutaneous dosing of pregnant CD1 mice to 25 µg/kg of 
radioactive BPA, the percent of total administered dose recovered after 24 hours was 
45% in digestive tract, 21% in feces, 5% in urine, 4% in fetal litter, 2.5% in liver, and 
1.8% in bile (Zalko et al., 2003). Also, in a rat uterine perfusion model when 2 µM of 
BPA-glucuronide was administered for 20 minutes, the conjugate was shown to pass 
through the placenta using Mrp1 and Oat4a1 transporters and become deconjugated in the 
fetal liver and amniotic fluid (Nishikawa et al., 2010). The few studies that have 
attempted to determine BPA toxicokinetics in humans show major flaws in dose 
frequency, analytical techniques, sample size, and selection of sample population 
(Teeguarden et al., 2011; Volkel, et al., 2005; Volkel, et al., 2002). Traditional methods 
of assessing BPA toxicokinetics are especially difficult in human pregnant adults and the 
developing fetus, but if tissues are available, biomonitoring with sensitive analytical 
techniques may be a first step to addressing the BPA knowledge gap. 
 The exposure-disease relationships in humans identified through epidemiological 
studies currently lack important mechanistic data that inform us about direct alterations in 
structure and function. These subtle exposure-dependent changes can gradually manifest 
as diseases much later in life, most likely occurring through epigenetic mechanisms 
(Gluckman, Hanson, & Low, 2011). DNA methylation at cytosine-guanine dinucleotides 
(CpG) is one commonly studied epigenetic marker that undergoes extensive 
reprogramming during pre-implantation and gametogenesis in early fetal development 
followed by tissue-dependent epigenetic differentiation (Faulk & Dolinoy, 2011). Several 
animal studies have already identified methylation as an important intermediate in BPA 
 
57 
related adverse health outcomes (O. S. Anderson, et al., 2012; Bromer, et al., 2010; S. M. 
Ho, W. Y. Tang, J. Belmonte de Frausto, & G. S. Prins, 2006). Research addressing 
human BPA-methylation associations is necessary especially throughout early 
development. Tissue utilized for biomonitoring can also be an excellent source for 
recognizing early dose-dependent changes that occur in expression and regulation.  





 trimester human fetuses, the aim of this study is to assess tissue-specific BPA 
concentrations, biotransformation gene expression, and exposure-dependent effects on 
global methylation. Identifying tissue-specific differences in BPA concentration and 
xenobiotic metabolizing enzyme expression will inform BPA toxicokinetics for 
improving human PBPK models specific for the developing fetus. The investigation of 
tissue-specific global methylation differences is particularly important for understanding 
BPA toxicodynamics and identifying early exposure-dependent regulatory changes that 
may lead to long-term adverse health effects.  
 
 
3.3 Methods and Materials  
Sample selection 
For this project, we took a subset of the fetal liver specimens from the extended 
sample clinical cohort (N=50) and acquired matching tissue from the NIH-funded 
University of Washington Laboratory for the Study of Human Embryology (LSHE) fetal 





 trimester fetal liver samples at the Wadsworth Center (New York State 
 
58 
Department of Health), indicating broad exposure ranging from below limit of 
quantification (LOQ) up to 96.8 ng/g of total tissue BPA (Nahar, Liao, Kannan, & 
Dolinoy, 2013). In particular, we identified fetal kidney (N=12) and placental (N=12) 
tissues matching BPA-characterized fetal liver samples that represent low exposure (total 
BPA: 1.2-2.9 ng/g; N=6) and high exposure (total BPA: 25.1-53.7 ng/g; N=6), for which 
sufficient sample was available for BPA quantification and DNA/RNA extraction.   
 
Tissue BPA analysis and quality control 
All flash-frozen fetal specimen were stored in polycarbonate-free tubing at -80°C 
and homogenized before processing.  Like liver specimen, both free BPA and BPA 
conjugates were quantified in matched kidney and placental samples using high-
performance liquid chromatography coupled with API 2000 electrospray triple-
quadrupole mass spectrometer (HPLC ESI-MS/MS). Free BPA and conjugated BPA 
were homogenized from tissue weighing 550-710 mg. As mentioned in the last chapter, 
several quality assurance and quality control measurements were implemented for BPA 
analysis, including a procedural blank to check for laboratory contamination. By the start 
of this project, the LOQ was improved to 0.05 ng/g; thus, fetal kidney and placental 
tissue concentrations below the LOQ were assigned a value of 0.035 ng/g, estimated from 
dividing LOQ by the square root of 2.  
  
RNA and DNA extraction  
Similar to the fetal livers, total RNA and DNA was isolated from matched frozen 
fetal kidney and placental tissue using the AllPrep DNA/RNA/Protein kit following 
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manufacturer’s instructions, (Qiagen, Valencia, CA). Approximately 10-20 mg of tissue 
was homogenized in 600 µL of Buffer RLT solution (containing 1% β-mercaptoethanol) 
for 2 min at 20 Hz (2x) in the TissueLyser II (Qiagen). DNA quantity and purity was 
measured using the Nanodrop 2000 spectrophotometer (Thermo Scientific, Wilmington, 
DE), while the RNA concentration and purity was assessed using the Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA).  High quality mRNA was 
extracted from most specimens, with RNA integrity numbers (RIN) averaging 9.5 for 
kidney, 7.1 for placenta, and 7.6 for liver. RIN values for individual subjects and their 
respective tissues are reported in Table 3.1.  
 
cDNA synthesis and real-time quantitative PCR  
To produce complementary DNA, 1 µg of total RNA template was processed 
using the iScript cDNA synthesis Kit (Bio-Rad, Hercules, CA) as per manufacturer’s 
instructions.  The thermocycler settings for cDNA synthesis required incubation at 25°C 
for 5 min, 42°C for 60 min, and 90°C for 5 min. Four BPA-related metabolism genes 
(UGT2B15, GUSB, SULT1A1, and STS) along with three reference genes (GAPDH, UBC, 
and B2M) were previously optimized using fetal liver tissue and listed in Table 2.1.  
Using the same protocol from the last chapter, we amplified templates for each primer set 
for the new kidney and placenta samples using the same cycle parameters, running each 
unique reaction out in triplicate.  
The CFX Manager Version 1.6 software (Bio-Rad) was used to calculate the 
average threshold cycle (CT) across the triplicate runs. Unlike the previous chapter, 
results are reported as normalized expression with standard deviation. The normalized 
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expression of a particular target gene for each sample is calculated by normalizing the 
relative quantity (RQ=Efficiency primers 
[CT(minimum)-CT(target sample)]
 ) of the gene of interest to 
that of the reference genes.  
Normalized Expression = RQ gene of interest / [(RQGAPDH * RQUBC * RQB2M)^(1/3)] 
 
Bisulfite conversion, and LINE1 and LUMA global methylation analysis  
For the production of bisulfite converted (BSC) DNA, 1 µg of genomic DNA was 
treated with sodium bisulfite solution using the Qiagen Epitect kit automated on the 
Qiacube (Qiagen, Valencia, CA) following manufacturer’s protocol. The converted DNA 
was diluted in 20 µL of EB Buffer, yielding a final concentration of approximately 50 
ng/µL. Epitect methylated and unmethylated human BSC standards (Qiagen) were 
purchased and used as positive controls. 
Two independent DNA methylation assays were employed using the 
Pyrosequencing platform (Pyrosequencing, Westborough, MA) for global methylation 
analysis: the long interspersed transposable element-1 (LINE1) assay and the 
Luminometric Methylation Assay (LUMA). For amplification of LINE1, 2 µL of BSC 
DNA was added to a 30 µL PCR reaction containing 15 µL of HotStarTaq master mix 
(Qiagen), 375 nM forward primer, and 187.5 nM of biotin-labeled reverse primer. LINE1 
product amplification was set up using the following PCR cycling parameters: 95°C for 
14.5 minutes followed by 45 cycles of 95°C for 30 sec, 58°C for 30 sec, and 72°C for 30 
sec, then by 5 min at 72°C.  After amplicon verification via gel electrophoresis, 10 µL of 
PCR product was added to LINE1 sequencing primers and analyzed using a pre-
determined sequence to analyze run. Each amplicon was run in duplicate in the 
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PyroMark™Q96 MD Pyrosequencing System. The PyroMark software computes % 
methylation at 4 CpG sites across the assay for each sample and control.  Primer 
information is detailed in Table 3.2 and previously described (Virani et al., 2012).  
Unlike LINE1, LUMA detects methylation at 5’-CCGG-3’ sequences both within 
and outside of repetitive elements across the genome. This restriction digest based assay 
requires unconverted genomic DNA and MspI, HpaII, and EcoRI restriction enzymes, as 
described previously (Bjornsson et al., 2008; Karimi et al., 2006). For each sample digest, 
two parallel reactions were set up containing 300 ng of genomic DNA, an internal 
standard enzyme (5 units of EcoRI), and 10x Buffer Tango™ with BSA (Fermentes). We 
incubated these mixtures at 37°C for 4 hours after adding 5 units of a methylation 
insensitive (MspI) enzyme to one reaction, and 5 units of methylation sensitive enzyme 
(HpaII) to the other.  Digested products were assessed in duplicates using the PyroMark 
MD SNP software using the nucleotide dispensation sequence order: 
GTGTCACATGTGTG. Percent global methylation results were calculated by looking at 
the ratio of digested versus undigested CCGG sites using the following equation:   
  1−[(HpaII(G)/EcoRI(T))/(MspI(G)/EcoRI(T))] × 100 
In the equation, G and T represent pyrosequencing signal peak intensities from the 3
rd
 G 
and T nucleotides of the dispensation order.  
 
Statistical analysis 
 Univariate analyses were conducted across all exposure, gene expression, and 
global methylation variables across the different tissue types. Mean differences across 
matched tissue were evaluated using ANOVA with Tukey post-hoc analysis. To test the 
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association between BPA and mRNA expression, we identified the Pearson’s correlation 
coefficient and p-value between BPA species and individual assays for each tissue type.  
Pearson’s correlation analysis was used to test the association between total BPA 
concentration and average LUMA methylation for each tissue type. The LINE1 assay 
evaluates % methylation across 4 adjacent CpG sites per reaction. To account for 
correlations between sites for each reaction, a linear mixed effects model was used.  
While total BPA concentration was held as the fixed effects and percent methylation was 
used as the dependent variable, CpG site number was used as the random effect. For each 
model tested using kidney, liver, and placental samples, the inter-subject variability was 
higher than the variability across CpG sites. All statistical analyses for this project were 
conducted using the stats, epicalc, and lme4 packages in R (version 2.14.2; The R 




BPA concentrations across tissue 
 Subjects with above average total BPA in liver and subjects with below average 
total BPA in liver that had matching placenta and kidney specimens were first identified. 
The average was defined previously using the normal distribution of the full N=50 fetal 
liver cohort (Nahar, et al., 2013).  We classified N=6 subjects (A-F) into the high 
exposure group (total liver BPA: 25.1-53.7 ng/g) and N=6 subjects (G-L) into the low 
exposure group (total liver BPA: 1.2-2.9 ng/g), representing a 10 fold difference in 
concentrations between the groups. Given these differences in liver concentrations across 
 
63 
the groups, we expected similar patterns in BPA concentrations in placenta and fetal 
kidney specimens.  
In general, free and conjugated BPA concentrations for placenta and fetal kidney 
significantly differed from matched fetal liver with p-values at 0.005 and 0.004, 
respectively.  In Table 3.3, 100% of liver, 100% of kidney, and 83% of placental samples 
reported detectable concentrations of free BPA. While all 12 fetal liver samples exhibited 
detectable concentrations of conjugated BPA, the conjugated species was detected in only 
58% of kidney and 42% of placental samples. Free BPA was higher than conjugated BPA 
concentrations across most tissues except for the placenta in subject H. Figure 3.1 
displays BPA for individual subjects (A- L) and their tissue types, with free BPA species 
in panel A and conjugated BPA species in panel B. No obvious patterns were observed 
for either free or conjugated BPA concentrations. Unlike fetal liver specimen, BPA 
concentrations did not significantly differ by low and high exposure group for matched 
placentas (free p-value: 0.532, conjugated p-value: 0.336) or for matched kidneys (free p-
value: 0.377, conjugated p-value: 0.735). The discrepancy in BPA concentrations from 
one tissue to another in any given subject is likely due to physiological differences across 
organs related to xenobiotic transport, metabolism, and storage. Interestingly, a few 
specimens, especially in the placenta, displayed free BPA or BPA conjugates at 
concentrations below the LOQ.  
 
BPA-specific XME gene expression across tissue 





 trimester developing fetus. Each tissue was analyzed for mRNA expression for 
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xenobiotic metabolizing enzymes important for the conjugation (UGT2B15, SULT1A1) or 
deconjugation (GUSB, STS) of BPA, as denoted by Figure 1.1.  Figure 3.2 illustrates the 
normalized expression pattern of these four genes together for each tissue type. In 
general, the three organs have distinct metabolic profiles with varying mRNA levels.   
For the glucuronidation conjugation and deconjugation pathway, kidney and 
placenta GUSB expression were significantly higher than UGT2B15 expression (p-values 
<0.001). Although the two genes did not significantly differ from one another in liver (p-
value: 0.727), the mRNA levels were relatively higher in liver compared to other organs. 
For the sulfation conjugation and deconjugation pathway, SULT1A1 expression was 
significantly higher than STS expression in kidney and liver specimen (p-values <0.001). 
The placenta mRNA profile is quite distinct given that STS expression is significantly 
higher than the remaining BPA-metabolism genes. In the developing fetus, these 
expression patterns may denote higher activity for BPA-glucuronide deconjugation 
across the three tissues, and higher activity for BPA sulfation in all tissues except for the 
placenta.  
 
BPA concentration and XME gene expression associations across tissue 
 The sulfotransferase and UDP-glucuronosyltransferase enzymes contribute to 
higher concentrations of BPA-glucuronide and BPA-sulfate conjugates, while the steroid 
sulfatase and β-glucuronidase deconjugation enzymes contribute to higher concentrations 
of the parent compound. Since we did not separately measure the two BPA conjugates, 
we only assessed the correlation between free BPA and the four metabolism genes for 
each tissue, expecting a positive correlation with deconjugating genes and negative 
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correlation with conjugating genes. As noted in Table 3.4, most associations were 
negative and weak across fetal liver, fetal kidney, and placenta. Furthermore, no 
significant BPA-expression correlations were identified across each tissue (p-values 
>0.200).  
   
Global methylation across tissue 
 LINE1 retrotransposons are found in approximately 17% of the genome (Ostertag 
& Kazazian, 2001), and CCGG sequences assayed by LUMA make up 8% of all CpG 
sites in the epigenome (X. Xu et al., 2012). Here, we measured both LINE1 and CCGG 
global DNA methylation across three matched tissues. Average LINE1 methylation 
across N=12 subjects was 77.9% in kidney, 79.5% in liver, and 58.3% in placenta, while 
the average LUMA methylation was 77.0% in kidney, 66.4% in liver, and 59.2% in 
placenta. Although the LINE1 and LUMA assays measure different parts of the genome, 
methylation values were comparable especially across the kidney and placenta samples. 
The standard deviations for each tissue, however, were greater for LUMA compared to 
LINE1 methylation measurements.  As expected, there were significant differences in 
methylation from one tissue to another within an individual subject. For example, both 
LINE1 and LUMA assay exhibited significant hypomethylation in placenta compared to 
matched liver and kidneys (p-values <0.001, Figure 3.3).  
 
BPA concentration and global methylation associations across tisue 
 While free BPA is the only species that can actively bind to hormone receptors, it 
is uncertain whether both free and conjugated forms influence epigenetic processes. 
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Therefore, we reported the relationship between global methylation and total BPA 
concentrations instead of the separate BPA species. As listed in Table 3.5, the Pearson’s 
correlation between average % methylation using LUMA and total BPA was not 
significant with p-values at 0.934, 0.113, and 0.453 for kidney, liver, and placenta, 
respectively. Similarly, we did not identify any significant associations between average 
LUMA methylation and free BPA or BPA conjugates (data not shown).  
 Each LINE1 reaction reads methylation values at 4 adjacent CpG sites. To 
consider site-specific differences, a mixed effects model was used to test the relationship 
between total BPA and LINE1 methylation at all four sites, separately for each tissue. 
The β1 estimates in Table 3.5 for the BPA-methylation relationship were insignificant for 
kidney and liver, but significant for placenta. Accounting for CpG site-specific variation, 
with every 1 ng/g increase in total BPA, there was a 0.23% increase in global methylation 
in placental samples (p-value <0.002). A significant association was also observed with 
LINE1 methylation and free BPA but not with conjugated BPA in placenta (data not 





 The internal dose for nutrients, pharmaceuticals, and toxicants may differ across 
various tissues within an individual, depending on the fat content, capacity for uptake and 
elimination, or metabolic potential of an organ. Which biological sample is selected for 
exposure assessment depends on tissue availability, cost and ease of extraction, 
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optimization of environmental analysis in matrix, and expected adverse effects. Research 
concerning the internal dose of BPA across various human tissues is currently limited. 
Geens et al. were the first to measure BPA concentrations across several postpartum 
organs in adults, detecting 1-10 ng/g of free BPA across liver, brain, and adipose tissues 
in N=11 human subjects (Geens, Neels, & Covaci, 2012). In this study, we quantified 
both free and conjugated BPA across three organs from individuals representing a 
sensitive population, with N=6 from a low exposure and N=6 from a high exposure 





trimester pregnancy tends to accumulate in fetal liver (median free: 7.09 ng/g) more so 
than in placenta (median free: 1.36 ng/g) and fetal kidney (median free: 0.536 ng/g), 
regardless of initial exposure. In the first pregnancy-related tissue biomonitoring studies, 
researchers detected an average of 11.2 ng/g of free BPA in term placenta from 37 
German women, and reported 5.7-22.2 ng/g of free BPA in 10 out of 49 term placenta 
from Spanish women (Jimenez-Diaz, et al., 2010; Schonfelder et al., 2002).  Recently, a 
Health Canada study reported free BPA in early and mid-gestational fetuses at 
concentrations of 0.6-64.0 ng/g in placenta and 1.3-27.0 ng/g in fetal liver (J. Zhang, 
Cooke, Curran, Goodyer, & Cao, 2011). Unlike our study, samples were not matched and 
free BPA was detected at higher rates and concentrations in placenta compared to fetal 
liver, as summarized in Figure 2.2.   
 Most of the findings from these tissue biomonitoring studies suggest considerable 
BPA exposure directly to the human fetus during development. The exact range of tissue 
concentration and detection frequency from one population to another may differ, but is 
likely explained by the various sensitivities and analytical techniques employed. The 
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HPLC coupled ESI-MS/MS method utilized is an important strength of this project, given 
its high sensitivity (LOQ= 0.05 ng/g) and use as the “gold standard” for BPA analysis (L. 
N. Vandenberg, et al., 2010). Even with stringent quality controls throughout tissue 
processing and analysis in the lab, BPA contamination from tissue acquisition and 
storage is a major concern for all human BPA biomonitoring studies.  While the details of 
the extraction procedure for each fetus were not available to us, findings from this study 
suggest that BPA contamination during tissue acquisition is negligible in this sample set.  
Assuming similar instrument use within a given procedure and consistent background 
contamination at the collection site, any BPA contamination occurring throughout 
surgical processing would be expected to have distributed equally to the various matched 
tissues within a single donor, which were then immediately flash frozen. In this study, 
several subjects with measurable levels of free BPA in liver showed undetectable 
concentrations in matching placenta and low concentrations in kidney, suggesting that 
free BPA was attributed to in utero instead of ex vivo contamination. Furthermore, tissue 
storage in polypropylene tubing at -80°C with minimal freeze-thaw events should negate 
contamination during storage. Still, even if some contamination occurred during tissue 
extraction, the presence of biologically activated BPA conjugates in our fetal tissue 
demonstrates considerable exposure in utero. The disadvantage with observing major 
differences in tissue concentrations within an individual is the inability to use one tissue 
as a proxy for another. While the placenta may be an accessible tissue, according to these 
findings, BPA concentrations in this tissue do not accurately represent and may 
underestimate the internal dose in fetal liver and other target sites.  
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 Identifying toxicokinetic characteristics, such as prevailing detoxifying reactions, 
may explain tissue differences in BPA concentrations observed within subjects.  
Therefore, we examined mRNA expression specific for BPA metabolism across placenta, 
fetal liver, and fetal kidney.  In this study, we noted distinct tissue-specific expression 
profiles, with the highest SULT1A1, GUSB, and UGT2B15 mRNA levels in fetal liver 
compared to other tissues. The higher GUSB expression compared to UGT2B15 
expression previously identified in liver was also observed across placenta and fetal 
kidney (Nahar, et al., 2013). As expected, SULT1A1 expression was higher than STS 
expression in fetal tissues (O'Shaughnessy, Monteiro, Bhattacharya, Fraser, & Fowler, 
2013), but with opposite trends in placenta. While sulfation reactions are generally higher 
in the developing fetus for xenobiotic defense, high STS activity is necessary in the 
placenta for the regulation of estrone and DHEA (Stanley, et al., 2005). If mRNA levels 
accurately reflect enzyme activity, findings suggest that BPA-glucuronide and BPA-
sulfate conjugates in maternal circulation are more likely to be cleaved back into the 
estrogenic parent form in the placenta. Once in the fetal liver, both BPA-glucuronide 
conjugation and deconjugation may occur, but any excess free BPA can become 
conjugated to BPA-sulfate. In the fetal kidneys, similar reactions can occur, although at a 
lower rate. Future biomonitoring studies will require separate measurements of BPA-
glucuronide and BPA-sulfate, as new evidence reveals that BPA-sulfate may be the 
predominant conjugate in the human fetus (Gerona, et al., 2013).  
To evaluate toxicokinetics in this project, we only assessed biotransformation 
through gene expression of XMEs that are important for BPA across various tissues. 
Simply correlating BPA concentrations with mRNA expression did not reveal significant 
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associations for any particular organ. As mentioned in chapter 2, the null results suggest 
that other factors may influence BPA toxicokinetics such as 3'-phosphoadenosine-5'-
phosphosulfate (PAPS) and UDP-glucuronic acid cofactor concentrations, protein 
modification of enzymes, and xenobiotic transporters for absorption and elimination 
across tissue. Variability in the transporters specific for free BPA or its conjugates, 
although currently unknown, are likely to explain the different concentrations observed in 
our matched tissues. For example, a particular set of transporters may be required for 
BPA to actively cross the placenta and then be eliminated from the fetal kidneys into 
amniotic fluid, bypassing bioaccumulation in these organs.  
 Despite bioaccumulation, individual organs may exhibit differential sensitivity to 
BPA, eliciting distinct biological responses. Environmental exposures during sensitive 
windows of development can alter the baseline regulatory markers or developmental 
trajectories that lead to noticeable biological effects at a later time point (Faulk & 
Dolinoy, 2011). Thus, epigenetic regulatory markers such as DNA methylation may be 
the best biomarker for assessing short-term biological effects from exposure, especially if 
longitudinal data is unavailable. Global DNA hypomethylation is commonly found in 
several adverse health outcomes such as cancer, indicating genomic instability (Torano, 
Petrus, Fernandez, & Fraga, 2012). Utilizing two crude global methylation assays in this 
study, we identified significant differences in average methylation across tissues, where 
placental samples showed the lowest global methylation levels.  Several studies have 
already reported low CpG methylation in placenta versus other tissues using a variety of 
global methylation techniques (Ehrlich et al., 1982; Fuke et al., 2004). For example, Price 
et al. observed LINE1 methylation at approximately 60% in placenta but around 80% 
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methylation in fetal somatic tissue (Price et al., 2012). DNA hypomethylation, especially 
within repetitive elements, is assumed to play an evolutionary role in invasive and 
proliferative function of the placenta.  
  Assays like LUMA and LINE1 are currently used as a surrogate for global DNA 
methylation measurements, each representing different genomic regions with varying 
strengths and weaknesses. In a recent methods paper, results from LINE1 showed the 
least replicate variability akin to the HPLC gold standard, while LUMA values were most 
variable (Lisanti et al., 2013).  Large variability, coupled with a relatively small sample 
size in our LUMA data, may have masked any BPA concentration-dependent effects on 
global methylation. Using the less variable LINE1 assay, we identified a small but 
significant positive association between BPA concentration and methylation only in the 
placenta. Still, several limitations of this study necessitate a cautious interpretation of 
results and further investigation into this association. Global methylation assays are 
crude, efficient methods to look at exposure-dependent changes, but BPA may influence 
methylation in a locus or gene-specific manner. Furthermore, epigenome-wide 
methylation patterns are not only tissue-specific but also cell-specific (Michels et al., 
2013). Thus, once cell-specific methylation techniques are optimized and cost-effective, 
BPA’s impact on cell-specific methylation changes should be assessed. Exposure-
epigenetic associations are also likely to differ by the type of epigenetic marker 
examined. In recent years, other DNA base modifications like 5-hydroxymethylcytosine 
(5hmC) have been discovered with evidence for its role in fetal liver development 
(Ivanov et al., 2013).  Nevertheless, this is the first study to report environmentally 
relevant BPA concentrations and altered capacity for metabolism across several human 
 
72 
tissues. Although subtle BPA dependent changes were identified, findings support the 


























Table 3.1 RNA Integrity Number Across Individual Tissues and Subjects 
RNA Integrity Number (RIN) 
Subject Placenta Liver Kidney 
A 8.0 8.5 9.4 
B 3.0 9.0 9.6 
C 3.6 8.4 9.5 
D 8.8 7.8 9.6 
E 7.5 7.4 9.7 
F 8.8 8.6 9.6 
G 7.7 5.8 9.6 
H 7.2 4.5 9.6 
I 7.1 8.7 9.6 
J 8.7 6.4 9.7 
K 7.0 8.2 9.1 




Table 3.2 LINE1 PCR and Pyrosequencing Information 
 Sequence  




Sequencing Primer 5’-AGGTGTGGATATAGT-3’ 




Table 3.3 BPA Concentrations Across All Tissue Types 














Kidney (N=12) 100 0.536 0.079-11.10 58 0.092 <LOQ-0.751 
Liver (N=12) 100 7.085 0.540-50.50 100 2.255 0.450-15.85 
Placenta (N=12) 83 1.355 <LOQ-25.40 42 0.071 <LOQ-9.810 
ANOVA*   0.0053   0.0038 





Table 3.4 Pearson’s Correlation Between Free BPA and Gene Expression (N=12 Per 
Tissue) 
 Fetal Kidney Fetal Liver Placenta 
GUSB 
-0.260, 






























Table 3.5 Associations Between Total BPA Concentration and Global Methylation 
 LINE1† LUMA 
β1 Estimate p-value Pearson’s 
correlation 
p-value 
Kidney 0.066 0.424 0.027 0.934 
Liver 0.021 0.425 0.482 0.113 
Placenta 0.225 0.002* -0.240 0.453 
† Mixed effects model controlling for random effect by CpG site  





















Figure 3.1 Free and Conjugated BPA Concentrations Across Tissue from N=12 Subjects 
 
 
BPA concentrations differ across tissue and individuals. Subjects A-F (N=6) represent the high BPA 
exposure group while subjects G-L (N=6) represent the low BPA exposure group. Within each subject, 
three tissues were analyzed: placenta, fetal liver, and fetal kidney. Two separate graphs for all subjects and 









BPA-related XME gene expression profiles differ by tissue. The dot plot displays the normalized gene 
expression values for all 12 subjects for four genes: GUSB, UGT2B15, STS, and SULT1A1. Each panel 
shows the expression profiles by tissue type: (A) fetal kidney (B) fetal liver and (C) placenta. When an 
ANOVA test was conducted across the three tissues for GUSB, UGT2B15, STS, and SULT1A1 separately, 
























Figure 3.3 LINE1 and LUMA Global Methylation Across Tissue 
 
 
Global methylation levels differ across tissue. Boxplots represent the average global % methylation 
values for placenta, fetal liver, and fetal kidney using the assay for (A) LINE1 on the left panel and (B) 
LUMA on the right panel. Average LINE1 methylation was 77.92% in kidney, 79.49% in liver, and 
58.27% in placenta, while average LUMA methylation was 76.99% in kidney, 66.42% in liver, and 59.15% 
in placenta. Percent global methylation measured by LINE1 and LUMA were significantly different across 
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CHAPTER 4  
Bisphenol A Associated Alterations in Candidate Biotransformation Gene 
Expression and Regulation in Human Fetal Liver  
 
Text modified from Nahar, M. S., Kim, J. H., Sartor, M. A., & Dolinoy, D. C., 2014. 
Bisphenol A-associated alterations in the expression and epigenetic regulation of genes 
encoding xenobiotic metabolizing enzymes in human fetal liver. Environ Mol Mutagen, 
9(10), 21823. Permission for reuse approved by Rightslink and Copyright Clearance 




Alterations in xenobiotic metabolizing enzyme (XME) expression across the life 
course, along with genetic, nutritional, and environmental regulation, can influence how 
organisms respond to toxic insults. In this study, we investigated the hypothesis that in 
utero exposure to the endocrine active compound, bisphenol A (BPA), influences 





 trimester human fetal liver specimens quantified for BPA 
concentrations, we examined XME gene expression using qPCR Array (N=8) and RNA-
sequencing (N=12) platforms. Of the greater than 160 XME genes assayed, two phase I 
and twelve phase II genes exhibited significantly reduced expression with higher BPA 
concentrations, including isoforms from the carboxylesterase, catechol o-
methyltransferase, glutathione s-transferase, sulfotransferase, and UDP-
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glucuronosyltransferase families. When the promoters of these candidate genes were 
evaluated in silico, putative binding sites for the E-Twenty Six (ETS) and Activator 
Protein1 (AP1) related transcription factor families were identified and unique to 97% of 
all candidate transcripts. Interestingly, many ETS binding sites contain cytosine-guanine 
dinucleotides (CpGs) within their consensus sequences. Using Methylplex-next 
generation sequencing (M-NGS) data, we identified regions of variable methylation that 
overlap with ETS binding sites to design site-specific DNA methylation assays. 
Quantitative analysis of CpG methylation of three candidate genes was conducted across 
N=50 samples and analyzed with tissue BPA concentrations. Higher total BPA 
concentrations were associated with increased site-specific methylation at COMT (p-
value <0.005) and increased average methylation at SULT2A1 (p-value <0.020) 
promoters. While toxicological studies have traditionally focused on high dose effects 
and hormonal receptor mediated regulation, our findings suggest the importance of low 




A compound’s absorption, distribution, metabolism, and excretion via 
biotransformation pathways dictate its therapeutic or toxic potential. Specifically, 
changes in phase I and II xenobiotic metabolizing enzyme (XME) gene expression and 
activity can alter drug efficacy and toxicity, with the greatest discrepancies observed in 
children compared to adults (Alcorn & McNamara, 2003). Preliminary studies indicate 
that relative XME expression and activity among different classes and isoforms change 
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drastically throughout the life course (Hines, 2008).  For example, the phase II UDP-
glucuronosyltransferase isoforms, UGT1A1 and UGT1A6, are both expressed at low 
levels in the human fetus; while UGT1A1 attains adult levels within months after birth, 
the UGT1A6 isoform reaches adult levels at 10 years of age (McCarver & Hines, 2002). 
Therefore, the extent of biotransformation of a xenobiotic chemical is dependent on age 
and ontogeny, or the maturation of specific XMEs (Allegaert, van den Anker, Naulaers, 
& de Hoon, 2007). Much of our understanding of human XME ontogeny arises from 
adverse pharmaceutical exposures or diseases throughout birth and infancy, or 
extrapolations from rodent models (Saghir, Khan, & McCoy, 2012).  Comprehensive 
studies examining metabolism in early human fetal development are limited; for example, 
recent studies characterize only a handful of XMEs, such as steroidogenic enzymes in 2
nd
 
trimester fetal liver (O'Shaughnessy, et al., 2013) or cytochrome p450s and glutathione s-
transferases in fetal liver and adrenals (Wang et al., 2008). Evaluating ontogeny, 
especially throughout human gestation, is thus of great importance in assessing toxicity; 
however, obtaining suitable human specimens may pose ethical and technical challenges. 
In addition to drug metabolism, XMEs play an important role in steroid 
homeostasis, neuroendocrine function, and growth. Using feedback signaling, both 
endogenous and exogenous compounds help regulate XME ontogeny and subsequently, 
metabolic function. More recently, studies demonstrating the importance of hormonal 
regulation on the establishment of hepatic metabolism throughout pregnancy and 
development have emerged (Jeong, 2010; Kennedy, 2008).  Xenobiotics that can mimic 
endogenous hormones, such as bisphenol a (BPA), can potentially modify baseline 
hormonal regulation of xenobiotic metabolism and response to environmental stressors 
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during critical windows of development.  While endogenous and exogenous agents 
commonly act through nuclear or steroid receptor mediated pathways for modulating 
XME expression, currently there is considerable interest in exploring the role of 
epigenetic markers along with signal transduction in XME regulation (Klaassen, Lu, & 
Cui, 2011; Zhong & Leeder, 2013).  
To date, research addressing BPA’s influence on XME expression and activity 
has been limited to animal and in vitro models.  For example, rat hepatic microsome 
studies show that BPA inhibits cytochrome p450 enzymes, including activity for 
CYP1A2, CYP2C11, and CYP2E1 (Hanioka, Jinno, Tanaka-Kagawa, Nishimura, & 
Ando, 2000; Pfeiffer & Metzler, 2004), yeast and human liver microsome studies 
associate BPA with both competitive and noncompetitive inhibition of UGT1A6 
(Hanioka et al., 2008), and human endometrial Ishikawa cell line studies show increased 
ALDH3A1 expression following BPA exposure (Naciff et al., 2010). Interspecies 
differences in metabolism and/or relatively high BPA exposure levels, however, prevent 
the translatability of these findings to assess human risk.  
The influence of xenoestrogens on the maturation and regulation of phase I and II 
xenobiotic metabolizing enzymes have yet to be studied in humans. In this final 
dissertation chapter, we utilize high-throughput approaches for evaluating XME 
expression and regulation associated with tissue BPA concentrations. Here, we identify 
novel candidate XME genes that are associated with physiologically relevant 
concentrations of total BPA, assess relative abundance of these XME mRNAs in the 
developing human fetal liver, explore common regulatory factors for XME candidates, 
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and investigate DNA methylation as a potential mechanism influencing 
biotransformation response to BPA exposure. 
 
 
4.3 Methods and Materials  
Tissue sample selection 
While free BPA is the only species to activate receptor-mediated pathways, the 
role that conjugated BPA plays on non-receptor mediated mechanisms is currently 
unknown.  Thus, we used total BPA concentrations to identify exposure-dependent 
differences in gene expression and methylation. As described in chapter 2, total BPA 
concentrations measured in fetal liver tissue ranged from below the limit of quantification 
at 0.071 ng/g (LOQ/√2, where LOQ=0.1 ng/g) up to 96.8 ng/g (Nahar, et al., 2013). For 
candidate gene identification and quantification, samples were binned into low or high 
exposure categories based on total tissue BPA concentrations. The category descriptions 
are detailed for each technique below.  
 
RNA and DNA preparation 
As described in the previous two chapters, total RNA and DNA was isolated from 
all frozen liver tissue with quality and quantity assessed using the Nanodrop 2000 
spectrophotometer (Thermo Scientific, Wilmington, DE) and Agilent 2100 Bioanalyzer 
(Agilent Technologies, Santa Clara, CA).  Only high quality samples with RNA integrity 
number (RIN) >7 were used for RT
2
 Profiler PCR Arrays (N=8) and high-throughput 
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RNA-sequencing (N=12). For PCR gene expression analysis, RNA templates were 
converted to complementary DNA as previously described in chapter 2.  
 




 PCR Array 
 Differential mRNA expression of various genes from the XME pathway were 
assessed by using two different cataloged human arrays from SuperArray Biosciences 
(Frederick, MD): the Phase I Enzyme PCR Array (PAH-068E4) and the Phase II Enzyme 
PCR Array (PAH-069E4). Each SYBR Green-based 96-well PCR Array platform 
interrogates multiple genes and isoforms relevant to a specific biological pathway along 
with five reference genes and several controls per sample.  Based on the distribution of 
total BPA concentrations measured in 50 fetal liver samples (Nahar, et al., 2013), the 
median BPA concentration (3.44 ng/g) was used as a cutoff for group categorization. The 
final samples were chosen based on the highest RIN scores and a >10 fold difference in 
average total BPA between low and high exposure groups. Four liver RNA samples 
exhibiting low total BPA concentrations (1.2-2.9 ng/g) and four liver RNA samples 
exhibiting high total BPA concentrations (35.4-56.1 ng/g) were submitted to the UM 
Sequencing Core facility and run on both PCR Array platforms using the ABI Prism 7900 
HT Sequence Detection System (Applied Biosystems).  
 
PCR Array gene expression analysis 
The threshold cycle (CT) was obtained for each target gene, and an average 
reference CT was calculated for the five endogenous reference genes: β2-microglobulin 
(B2M), hypoxanthine phosphoribosyltransferase I (HPRT1), ribosomal protein L13a 
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(RPL13A), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and β-actin (ACTβ).  
Positive PCR and reverse transcription controls were either undetected or had an 
extremely high CT value. Results are reported as ∆CT, which represents the difference 
between the CT of the target gene versus the average CT of the reference genes. The 
average ∆CT of the low exposure samples were subtracted from the average ∆CT of the 
high exposure samples to obtain the ∆∆CT value, and fold change was calculated as 2
- 
∆∆CT
. A linear model designed for microarray analysis was utilized to increase the power 
to detect fold change differences in target arrays by pooling information using the limma 
package of Bioconductor in R statistical software version 2.13.2 (Smyth, 2004).  
Furthermore, p-values were adjusted for multiple comparisons using false discovery rate 
(Benjamini & Hochberg, 1995). Candidate genes were chosen based on greater than 2 
fold or less than 0.5 fold change and p-value <0.05.  
  
Next generation RNA sequencing 
To characterize the relative mRNA abundance of XMEs in human fetal liver, 
regardless of sex or exposure, we utilized information from a second set of samples 
(N=12, including 3 samples also used in the PCR Arrays) submitted for high throughput 
next generation mRNA sequencing (RNA-seq) using the Illumina HiSeq 2000 platform 
(Illumina, San Diego, CA).  General workflow for next generation sequencing library 
construction consists of enrichment of poly-A RNA, fragmentation, RNA clean up, 
cDNA synthesis using hexamer primers, end repair, and adaptor ligation, as previously 
described (Sengupta et al., 2011). The raw sequencing image data was analyzed with the 
Illumina analysis pipeline, using single reads up to 150 base pairs (bp) in length. Over 
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438 million reads across 12 samples were obtained, with an average read number of 36.5 
million per sample. The FastQC tool was used to perform quality control checks on raw 
data.  In order to utilize reads with the best quality calls (FastQC per base sequence 
quality score above 28), sequences were trimmed to 70 bp in length, and reads were 
aligned to the hg19 human reference genome using TopHat. Parameters with the best 
alignment and increased search time were used in order to improve sensitivity. After 
removing duplicate reads resulting from PCR duplicates with SamTools, transcript 
abundance was measured by CuffDiff v2.0.1 software as fragments per kilobase of exon 
per million fragments mapped (FPKM). Total fragment reads were calculated and 
normalized across 12 samples. Approximately 152 genes of the phase I and phase II 
genes on the PCR Arrays were identified in the RNA-seq dataset along with their 
normalized FPKM reads.  The bottom and top quartile reads in FPKM are reported, 
indicative of low and high relative expression of phase I and phase II XME genes during 
development.  
 
Transcription factor binding site identification 
An in silico bioinformatics approach was used to identify common promoter 
regulatory elements within BPA-associated candidate genes identified from the PCR 
Arrays. Gene2Promoter (Genomatix, Munich, Germany) software utilizes position 
weight matrices to predict transcription factor binding sites (TFBS) 500 bp upstream and 
100 bp downstream of transcription start sites (TSS) of candidate genes (Cartharius et al., 
2005). Using MatInspector, fasta-formatted input sequences of the PCR Array candidate 
gene promoters were compared, and common transcription factors were clustered 
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together into TFBS families or “matrix families” based on similarities in binding domain 
or function. Regulatory families were reported when TFBS were identified in >97% of all 
relevant transcripts of the candidate XME genes.  
 
Methylplex next generation sequencing profiles 
In a parallel study, we used the epigenome-wide Methylplex next generation 
sequencing (M-NGS) platform to identify novel exposure-dependent regions of altered 
methylation within a subset of the fetal liver specimens (N=18).  For each sample, the 
Methylplex library synthesis and GC-enrichment was carried out using a proprietary kit 
(Rubicon Genomics, Ann Arbor, MI). Subsequent library sequencing took place at the 
UM DNA Sequencing Core using the Illumina HiSeq platform, which produces 100 
cycles of single-end reads for each sample. Detailed protocols for M-NGS library 
construction, sequencing, and alignment have been described previously (Kim et al., 
2014). Using the Illumina analysis pipeline, we obtained approximately 104 million reads 
per sample (ranging from 78 to 125 million reads) with 83.9% of these reads uniquely 
mapped to the human hg19 reference genome.  For this dissertation, we mined the 
methylome dataset to extract the methylation reads 5000 bp upstream and downstream 
surrounding the TSS for our candidate genes to aid in our Sequenom methylation assay 
design. In particular, we report the compiled methylation profiles for three candidate 




Bisulfite conversion and Sequenom methylation analysis 
 To quantitatively assess methylation at biologically relevant promoter regions, we 
designed Sequenom assays for three of our candidate genes using Methylplex and 
Genomatix data across N=50 fetal liver bisulfite converted (BSC) DNA. Chapter 3 
describes the instructions for bisulfite conversion using the Qiagen Epitect kit. Epitect 
methylated and unmethylated human BSC samples (Qiagen) were used as positive 
controls.  T7 tagged primers for the moderately expressed CES2, COMT, and SULT2A1 
candidate genes were designed for promoter methylation analysis using the EpiDesigner 
Web tool (http://www.epidesigner.com/, Table 4.1). Candidate gene promoter regions 
containing consensus sequences for ETS related transcription factors were amplified 
using HotStarTaq master mix in a 30 µl PCR reaction. A standard HotStarTaq thermal 
cycling setting was used for the three assays with the following changes: CES2 required 
annealing at 56°C for 30 sec at 35 cycles, COMT required annealing at 60°C for 30 sec at 
35 cycles, and SULT2A1 required annealing at 56°C for 30 sec at 40 cycles.  
After in vitro transcription and uracil-cleavage of amplicons as previously 
described (Coolen, Statham, Gardiner-Garden, & Clark, 2007), promoter methylation was 
quantified using the mass-spectrometry based Sequenom MassArray EpiTYPER platform 
(Sequenom, San Diego, CA) in the UM DNA Sequencing Core. Associations between 
amplicon average DNA methylation and total BPA tissue concentrations were assessed 
using a linear mixed effects model. For this model, percent methylation was the 
dependent variable and CpG unit number was the random effect, while total BPA 
concentration, sex, and gestational age were set as fixed effects. The analysis 
incorporated multiple site-specific CpG units (4 for CES2 and SULT2A1; 17 for COMT) 
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and accounted for correlations between adjacent dinucleotides for each assay. The 
association between CpG site-specific methylation of ETS consensus sequences and total 
BPA was assessed using multiple linear regression after adjusting for sex and gestational 
age.  For each statistical analysis, regression diagnostics were used to identify samples 
that deviate from standard linear regression assumptions (e.g. constant variance and 
normal distribution of residuals). Residuals were determined to be within cook’s distance 
cutoff  (<1); thus no data points were excluded from the final analysis.  Complete 
methylation data was analyzed for the following number of samples:  N=50 for CES2 and 
COMT, and N=40 for SULT2A1. Due to technical limitations, 10 samples failed the 
SULT2A1 Sequenom assay, and SULT2A1 CpG site #1, which falls within the ETS 









 PCR Array, we analyzed 167 genes involved in 
xenobiotic metabolism (93 phase I and 74 phase II enzyme isoforms) in human fetal liver 
specimens. Based on gene selection criteria (p-value <0.05 and fold change >2 or <0.5), 
two phase I genes and twelve phase II genes exhibited altered expression based on low 
(1.2-2.9 ng/g; N=4) versus high (35.4-56.1 ng/g; N=4) tissue total BPA concentrations 
(Table 4.2). All differentially expressed candidate genes exhibited significantly decreased 
expression in liver samples exhibiting high compared to low tissue BPA concentrations.  
The phase I genes include the CES2 and CES5A carboxylesterase isoforms, while the 
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phase II genes include catechol o-methyltransferase (COMT), glutathione s-transferase 
(GSTA5), sulfotransferase (SULT2A1, 1B1, 6B1, 1C3), and UDP-glucuronosyltransferase 
(UGT1A3, 1A4, 1A6, 1A8, 1A9, 1A10).   
 
Relative expression levels of XME genes  
 RNA deep sequencing was employed to qualitatively characterize the relative 
expression of 152 of the 167 phase I and phase II XME genes contained on the PCR 
Arrays. While real time quantitative polymerase chain reaction (RT-qPCR) based 
techniques are the gold standard for quantitative expression, RNA-seq platforms are 
important for simultaneous characterization of hundreds or thousands of genes; thus, this 
platform was utilized for exposure independent comparative expression rather than 
identification of differential expression.  RNA-seq reads were reported as fragments per 
kilobase of exon per million fragments mapped (FPKM) using CuffDiff v2.0.1. Table 4.3 
depicts the bottom and top quartile FPKM reads separately for phase I and phase II XME 
gene isoforms, with PCR Array candidate genes in bold. 
For phase I XME genes, the epoxide hydrolase (EPHX), hydroxysteroid 
dehydrogenase (HSD), and monoamine oxygenase (MAO) genes were expressed at high 
levels while carboxylesterase and cyclooxygenase (PTGS) genes were primarily 
expressed at low levels.  In several instances, an isoform of a gene family exhibited low 
expression while a second isoform of the same family exhibited high expression. For 
example, while the alcohol dehydrogenase and aldehyde dehydrogenase isoforms, 
ADH1A and ALDH1A1, were both expressed at high levels, the ADH7 and ALDH3B2 
isoforms were both expressed at low levels. Similarly, the predominantly expressed 
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cytochrome p450 and flavin-dependent monoxygenase isoforms were CYP3A7 and 
FMO5, while the CYP11B2 and FMO2 isoforms were expressed at low levels.  
 Among the phase II genes, several methyltransferases (GAMT, HNMT) and the 
thiosulfate sulfotransferase (TST) gene were expressed at high levels, while many N-
acetyltransferase genes like arylalkalamine and arylamine N-acetyltransferases (AANAT, 
NAT2) were expressed at low levels. The more common conjugating XME families such 
as glutathione s-transferase, sulfotransferases, and UDP-glucuronosyltransferase 
displayed isoforms that were variably expressed.  
 Interestingly, several BPA-associated candidate XME genes identified through 




 trimester fetal liver. 
They include CES5A, GSTA5, SULT6B1, SULT1B1, SULT1C3, and the UGT1A related 
isoforms. While none of the differentially expressed genes were expressed at high levels 
in early development, CES2, COMT, and SULT2A1 showed moderate expression and 
were subsequently assayed for epigenetic analysis.  
 
Identification of common transcription factors in candidate genes 
 Genomatix was used to assess common transcription factor binding sites 500 bp 
upstream and 100 bp downstream of the TSS belonging to nine unique BPA-associated 
loci (all UGT1A functional genes are regulated by a common promoter). Two 
transcription factor families were common in at least 97% of the promoters of all relevant 
transcripts.  Both Activator protein1 (AP1) and E-twenty-six (ETS) related transcription 
factor binding sites were identified at least once in the promoter of each locus as seen on 
the graphical presentation in Figure 4.1 (depicted in purple and green, respectively). The 
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AP1 family consists of MAF and AP1 related factors such as BACH1/2, 
MAFA/B/F/G/K, NRL, NFE2L1/2/3 (NRF1/2/3), and NRL. The ETS family consists of a 
variety of transcription factors containing the Ets DNA binding domain including 
ELF1/2/4, ETS1/2, ETV1/4/5, SPI1/B/C, among others. The consensus sequence for each 
family and subfamily along with key transcription factors are listed in Table 4.4. 
Interestingly, a majority of transcription factor binding sites belonging to the ETS family 
contain CpG dinucleotides in the consensus sequence, especially in the ELF, ELK, and 
ETV subfamilies.  
 
Candidate gene methylation profiling 
M-NGS methylation reads were plotted every 100 bp for each sample in order to 
produce DNA methylation profiles of candidate genes and their promoters. The 
methylation profiles for CES2, COMT, and SULT2A1 displayed in Figure 4.2, Figure 4.3, 
and Figure 4.4 span 5000 bp upstream and downstream of the TSS (profiles for the 
remaining 11 genes are not shown).  The profiles show distinct differences in methylation 
read numbers and location of variable methylation from one gene to another. Regions of 
variable methylation that overlap with ETS consensus sequences, located approximately 
1600-1900 bp upstream of the TSS, were highlighted for both CES2 (Figure 4.2) and 
SULT2A1 (Figure 4.4). For COMT (Figure 4.3), the highlighted region also coincides 
with ETS transcription factor binding but does not show large variability in methylation 
reads. This region was chosen because the 300 bp section across the TSS has been noted 
for its CpG island and was successfully assayed showing significant associations between 
methylation and disease outcomes (Abdolmaleky et al., 2006; Q. Xu, Ma, Payne, & Li, 
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2010). All highlighted regions on the Methylplex figures were important for designing 
site-specific DNA methylation assays that may be biologically relevant.  
 
ETS-specific methylation analysis at candidate gene promoters 
We studied CpG methylation in and surrounding ETS transcription factor binding 
sites at the promoters of three candidate genes:  CES2, COMT, and SULT2A1. These 
genes were chosen based on relatively moderate expression levels across fetal specimens 
irrespective of age, sex, and exposure according to RNA-seq reads.   Figure 4.5 displays 
the genomic location of the methylation assays with number of CpG sites, CpG units, and 
ETS transcription factor binding sites. Each assay analyzes multiple CpG units: 4 for 
CES2 and SULT2A1, and 17 for COMT.  Methylation across all sites ranged between 89-
96% for CES2, 3-8% for COMT, and 59-81% for SULT2A1. Within each assay, we also 
focused on specific CpG sites located on the ETS consensus sequence: CpG site #3 for 
CES2 and CpG sites #30 & #31 for COMT. CpG site #1 for SULT2A1 falls within the 
ETS transcription factor consensus sequences, but was unresolvable with Sequenom.  
The average methylation across all detectable sites in the COMT assay was not 
significantly associated with tissue BPA after adjusting for age and sex (p-value: 0.108); 
however, one out of the two CpG sites spanning the putative ETS consensus sequence 
showed a significant positive trend (p-value: 0.002). An interquartile range (IQR; 10.93 
ng/g) increase in total tissue BPA was associated with 0.416% increase in COMT 
methylation at CpG site #31 (Figure 4.5; Table 4.5). Similarly, an IQR (8.28 ng/g) 
increase in total tissue BPA was associated with a significant 0.821% increase across all 
six SULT2A1 CpG sites (Figure 4.5; Table 4.5; p-value: 0.042). The CES2 assay, 
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however, displayed decreased site-specific methylation at CpG site #3 and average 
methylation across all sites with increasing BPA concentrations, although neither 




The impact of nutritional and environmental exposures on the human xenobiotic 
metabolism system during early development is not well understood. As previously 




 trimester fetal liver 
specimens, ranging from below the LOQ to 96.8 ng/g total BPA in tissue (Nahar, et al., 
2013). In the current study, we compared gene expression of over 160 XME genes within 
a subset of fetal liver specimens, dichotomized into low (1.2-2.9 ng/g; N=4) and high 
(35.4-56.1 ng/g; N=4) total tissue BPA. In general, 14 candidate genes were identified 
that exhibit significantly reduced expression in fetal liver with higher tissue BPA 
concentrations.  With the exception of the phase I carboxylesterase isoforms, CES2 and 
CES5A, the majority of BPA-related XME candidate genes belong to the phase II gene 
family.  
Traditionally, the induction of phase I enzymes following drug and xenobiotic 
exposure is commonly observed, but here we observe BPA-associated repression of 
predominantly phase II XME expression. Only a handful of studies have previously 
reported xenobiotic-dependent repression of primarily phase II metabolizing genes.  In a 
2008 study examining endocrine disruptors’ ability to modify estrogen bioavailability, 80 
µM of BPA or 70 µM of genistein exposure to ER-negative HepG2 cells was associated 
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with decreased expression of several phase II metabolism enzymes, including UGT2B7, 
UGT2B15, and SULT1E1 genes (Hanet et al., 2008).  Of our newly identified BPA-
associated XME genes, only the UDP-glucuronosyltransferases have been previously 
associated with BPA as identified from the Comparative Toxicogenomic Database 
(http://ctdbase.org/). When MCF7 cells were exposed to 10 nM of BPA instead of the 
control DMSO vehicle, there was a reduction in UGT1A3 mRNA expression (Buterin, 
Koch, & Naegeli, 2006).  In a second study, BPA was reported to competitively inhibit 
UGT1A6 and subsequently alter metabolism of serotonin in liver microsomes (Hanioka, 
Takeda, et al., 2008).   
Characterizing XME activity and regulation, especially throughout fetal 
development, is challenging given the difficulty in acquiring relevant human specimens 
from sensitive populations.  With our unique samples, we were able to compare relative 
expression for hundreds of genes simultaneously using mRNA-next generation 
sequencing technology. After compiling all XME related genes, the top and bottom 25% 
of normalized RNA-seq reads for phase I and phase II metabolizing enzymes were 




 trimester fetal liver specimen in humans, listed in Table 
4.2. Detectable protein levels of CYP2C9, CYP2C19, CYP3A4, CYP3A5, and CYP3A7 




 trimester human liver (Hines, 2007). Specific isoforms 
for other biotransformation proteins, such as alcohol dehydrogenase (ADH1A), epoxide 
hydrolase (EPHX1, EPHX2), glutathione s-transferase (GSTA1), and sulfotransferase 
(SULT1A1) have also been reported in the early fetal liver (Duanmu, et al., 2006; 
Omiecinski, Aicher, & Swenson, 1994; Smith, Hopkinson, & Harris, 1971; Strange et al., 
1989).  Activity of phase I and II enzymes vary between gene families and isoforms with 
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relative abundance drastically altering over time until adult levels are reached (Hines & 
McCarver, 2002; McCarver & Hines, 2002). Interestingly, a majority of the BPA related 
candidate genes that were identified exhibited relatively low RNA-seq reads as compared 
to other phase I and phase II metabolism genes.  Thus, the negative association between 
BPA and specific underdeveloped XME genes may be indicative of repressive effects or 
delayed maturation of the candidate XME genes to adult levels, potentially altering the 
response to toxicants later in life.  
BPA is commonly known to interact with nuclear receptors such as estrogen 
receptor (ERα and β), estrogen related receptor gamma (ERRy), pregnane X receptor 
(PXR), aryl hydrocarbon receptor (AhR), androgen receptor, and thyroid receptor 
(Molina-Molina et al., 2013; Wetherill et al., 2007).  More recently, studies suggest that 
endocrine active compounds (EACs) induce rapid responses via non-genomic signal 
transduction pathways, and disease susceptibility may depend on the coordination 
between genomic and non-genomic pathways (Watson, Jeng, & Guptarak, 2011). In this 
study, the co-repression of candidate genes warranted a closer look at common regulators 
in order to provide insight into novel mechanism of action for BPA that are relevant to 
the XME pathway.  In our bioinformatic investigation of regulatory sites, we identified 
binding sites for the highly conserved ETS and AP1 related transcription factors. 
Extracellular signals affecting the MAPK and JNK signaling pathways often converge 
both upstream and downstream at ETS proteins, which consist of over 25 family 
members that can heterodimerize with other transcription factor families, such as the Fos 
and Jun domains of AP-1 related proteins (Bassuk & Leiden, 1995; Kyriakis & Avruch, 
2001; Yordy & Muise-Helmericks, 2000). Combinatorial control of specific ETS and 
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AP1 factors, along with other regulators, is likely to influence transcriptional XME 
specificity during early fetal development, a period in which estriol (E3) predominates 
and activates non-genomic processes (Watson, et al., 2011). While evidence for estrogen 
receptor independent mechanisms for BPA is increasing, only a few studies thus far have 
investigated BPA’s influence on ETS and AP1 factor targets.  BPA has been reported to 
stimulate the PU.1 transcription factor, a relative of the SP1A, SP1B, and SP1C 
regulators, in promyelocytic cells for neutrophilic differentiation (Watanabe et al., 2003). 
In human embryonic kidney cells, BPA at µM concentrations activated Nrf1 and Nrf2 
transactivation activity and induced antioxidant response element (ARE) target genes 
(Chepelev et al., 2013). Subsequent studies are necessary to investigate specific ETS and 
AP1 transcription factors and their genomic localization using methods such as chromatin 
immunoprecipitation coupled with sequencing (CHIP-seq).  
Cis-acting regulation at ETS and AP1 related transcription factor binding sites 
and promoter occupancy, in addition to post-transcriptional modifications, may alter 
environmental response via signal transduction. In particular, DNA methylation at CpG 
sites along the consensus sequence motifs, especially for ETS, can inhibit transcription 
factor binding and transcriptional activity (Hollenhorst, McIntosh, & Graves, 2011).  In 
our in silico analysis, ETS proteins were prevalent in the candidate gene promoters and 
many of the ETS consensus sequences contained at least one CpG site. When Hogart et 
al. characterized epigenome-wide patterns across several different primary murine cells, 
ETS consensus sequences were overrepresented within methylated regions that were 
abundant especially in hematopoietic stem cells (Hogart et al., 2012). By overlapping 
ETS binding sites with variable regions of methylation from M-NGS data in our study, 
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we used a comprehensive approach to designing epigenetic biomarkers at biologically 
relevant targets in humans. In particular, we wanted to examine whether decreased 
expression along with increased tissue BPA concentrations were associated with 
increased promoter CpG methylation at ETS binding sequences. Both site-specific 
methylation at the COMT promoter and average CpG methylation at the SULT2A1 
promoter significantly increased with higher BPA concentrations, although the increase 
in DNA methylation was relatively modest.  The less than 1% increase in promoter 
methylation at the ETS sites of differentially expressed genes suggests that additional 
regulatory elements, including other epigenetic mechanisms, influence expression. For 
example, the environmentally sensitive MAPK signaling proteins can associate with 
chromatin modifying complexes and directly regulate histone modifications (Suganuma 
& Workman, 2012). Future work will require further integration of signal transduction 
pathways with various epigenetic mechanisms, including histone modifications and RNA 
interference, in response to environmental stress at critical windows of development.  
Traditionally toxicological studies employed enzymatic activity assays to 
understand xenobiotic metabolism in vitro or in animal models; however, analyzing 
protein activity in the developing fetal liver is far more difficult when access is limited to 
small amounts of sensitive biobanked specimens. With the improvement of real-time 
PCR and utilization of next generation sequencing, hundreds of genes can be reliably 
profiled simultaneously using small mRNA sample volume and compared to protein 
activity. In general, mRNA expression is a good proxy for protein level, but gene 
expression does not always correlate to protein abundance. This discrepancy can be 
attributed to differences in the rate of protein or mRNA synthesis and turn over, or post-
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transcriptional regulation (C. Vogel & Marcotte, 2012). Hence, examination of target 
protein activity and post-transcriptional modification of regulatory elements in suitable 
samples will be necessary in future studies for complete characterization of fetal 
xenobiotic biotransformation. Still, in the case that healthy specimens are available, 
longitudinal analysis of the development of the human XME pathway is challenging 
given the bioethical concerns for fetal tissue, especially in 3
rd
 trimester.  Despite these 
limitations, gene expression profiling, even at a narrow window of development, can be 
helpful for exploring early genomic regulation that occur with a changing environment.  
While the task of investigating BPA’s influence on XMEs may be clearer in 
animal models in which investigators exercise control over experimental design and 
model choice, here we utilize human fetal liver samples from an NIH-funded biobank. 
These samples are derived from individuals who may have been exposed to a wide array 
of compounds and maternal factors. Thus, a variety of unmeasured but related factors, 
such as co-exposure to other EACs, may confound our results.  
In the presence of endogenous hormones and growth factors, phase I and phase II 
XME gene expression and enzyme function matures until adult baseline levels are 
attained, either after birth, during childhood, or in adolescence. Therefore, exposure to 
environmental compounds, especially during early life when the capacity for xenobiotic 
metabolism is suboptimal, may increase susceptibility to disease in the developing fetus 
and children (Allegaert et al., 2008). When XME gene expression was compared in fetal 
liver exposed in utero to physiologically low and high BPA concentrations, subtle 
decreases in specific phase I and II XME genes were observed.  Although BPA may not 
immediately dysregulate essential proteins or directly cause disease, the EAC may stunt 
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XME maturation via signaling pathways and epigenetic mechanisms. Considering the 
daily and cumulative exposure to a myriad of compounds in humans, the inability to 





















Forwarda aggaagagagTTTTGGTTTTGTATATTTGGTGAGA 58.93 
310 
-1900bp to       
-1590bp Reverseb cagtaatacgactcactatagggagaaggctATTCAAACCCTAATTATCTCCCTCC 61.01 





Forwarda aggaagagagTTTTAGTTTTTTTATTTGGGAAGGG 60.00 
343 
-245bp to 
+98bp Reverseb cagtaatacgactcactatagggagaaggctAACAACCCTAACTACCCCAAAAAC 60.70 




Forwarda aggaagagagAGGTTGTTTTGTATAGATGTGGGTTAT 59.48 
294 
-1953bp to     
-1659bp Reverseb cagtaatacgactcactatagggagaaggctTCCCAACTACTCAAAAAACTAAAACA 59.56 
 
*Surrounding transcription start site (TSS) where (-) represents upstream and (+) represents downstream of TSS 
aAll forward methylation primers contain a 10mer tag on the 5’ end, represented in lower case letters  
bAll reverse methylation primers include a T7 promoter tag on the 5’ end, represented in lower case letters  





Table 4.2 Differentially Expressed Phase I and II XME Genes by BPA Exposure 
Xenobiotic 






Phase I CES2 
Carboxylesterase 
0.186 0.0495 
Phase I CES5A 0.124 0.0495 
Phase II COMT Catechol o-methyltransferase 0.245 0.0251 
Phase II GSTA5 Glutathione s-transferase 0.140 0.0495 
Phase II SULT2A1 
Sulfotransferase 
0.248 0.0251 
Phase II SULT1B1 0.159 0.0261 
Phase II SULT6B1 0.054 0.0261 
Phase II SULT1C3 0.185 0.0261 
Phase II UGT1A3 
UDP-glucuronosyltransferase 
0.122 0.0343 
Phase II UGT1A4 0.121 0.0284 
Phase II UGT1A6 0.249 0.0373 
Phase II UGT1A8 0.048 0.0251 
Phase II UGT1A9 0.094 0.0449 
Phase II UGT1A10 0.187 0.0261 
*Fold Change <0.5 is down regulation; Fold Change >2 is up regulation in high BPA exposure group 































Table 4.3 Bottom and Top Quartile Expression (FPKM Reads from RNA-seq) of Phase I 
and Phase II XME Genes in N=12 Human Fetal Liver 
Biotransformation 
Pathway 
Gene Family Names 
Low Expression   
(bottom 25%) 
High Expression  
(top 25%) 
Phase I 















Epoxide hydrolase  EPHX1, EPHX2 
Oxygenase FMO2, PTGS2 FMO5, MAOB 
Phase II 




GSTA1, GSTP1, GSTO1, 
MGST3, MGST1, MGST2 
Methyltransferase NNMT GAMT, HNMT 














Phase I XME genes with FPKM reads <0.1 and FPKM reads >9 represent the bottom and top quartile of 
XME expression. For phase II XME, the genes at the bottom and top quartile of XME expression exhibit 
FPKM reads <0.2 and FPKM reads >12, respectively. Genes in bold are BPA associated candidate XMEs 
identified from PCR Arrays. While these genes show low expression, the remaining candidate genes 



















Table 4.4 Consensus Sequences of Common Transcription Factor Binding Sites (TFBS) 














NFE2L1 (NRF1) vncGCGCabgcgcvnv 
NFE2L2 (NRF2) nmcCGGAagtgac 
NRL nncTGCTgasn 
ETS (Human and 
























The table displays individual transcription factors and their consensus sequence motifs for each TFBS 
family. The sequence motifs follow the standards set by the International Union of Pure and Applied 
Chemistry (IUPAC), with highly conserved nucleotides in bold. Upper case letters (A, C, G, T) show the 
most frequent nucleotides occurring at greater than 50% frequency. The degenerate code (R, Y, K, M, S, 
W) represents two nucleotides that occur at >75% frequency, but individually contribute to <50% 
frequency. All other frequency distributions are represented by the letter “n”. In particular, several motifs 






Table 4.5 Mixed Effects and Linear Regression Models Comparing Average or 
Individual CpG (within ETS binding sites) Methylation with BPA Concentration 
Methylation Assay N 
Change in % Methylation for an IQR Change 
in Tissue Total BPA (ng/g) 
p-value 
CES2     
Average (4 total CpG;                         
4 CpG units)a 
50 -0.008 0.953 
CpG #3b 50 -0.114 0.409 
COMT     
Average (30 total CpG;                     
17 CpG units)a 
50 0.080 0.108 
CpG #30b 50 -0.010 0.851 
CpG #31b 50 0.416 0.002 
SULT2A1     
Average (6 total CpG;                         
4 CpG units)a 
40 0.821 0.042 
 
Inter-quartile Range (IQR) = 10.93 ng/g for CES2 and COMT, and 8.28 ng/g for SULT2A1;  
a Mixed-effects model to account for multiple adjacent CpG sites, adjusted for gestation age and sex; 











Figure 4.1 Diagram Displaying Common Transcription Factor Binding Sites (TFBS) on Candidate XME Gene Promoters 
 
 
Diagram displaying conserved consensus sequence binding sites for AP1 (purple) and ETS (green) related factors.  The two groups represent transcription 
factor families at the promoters of BPA-associated candidate genes CES2, CES5A, COMT, GSTA5, SULT2A1, SULT1B1, SULT1C3, SULT6B1, and UGT1A1-10 
retrieved from MatInspector. The view includes 500 bp upstream and 100 bp downstream of the TSS. Although transcription factor binding sites were identified 


































Figure 4.2-4.4. Dot plots representing methylation profiles 5000 bp upstream and downstream of the 
TSS. Unadjusted methylation reads were graphed at every 100 bp fragment with individual dots 
representing N=18 fetal liver specimens. Regions highlighted in black were chosen for subsequent 
Sequenom methylation analysis. (A) The CES2 gene has three distinct regions with variable methylation 
including one peak at -1300 to -1800 bp upstream, and two peaks at 1700 to 1800 bp and 3600 to 3800bp 
downstream of TSS. An ETS site coincides within the variable region upstream, highlighted in black.  (B) 
The COMT gene also has three distinct regions of variable methylation: two peaks at -1200 to -1000bp and 
-1700 to -1800bp, and another at 2400 to 2900bp from TSS. While methylation variability was low, the 
region from -300 to 100bp around TSS was selected and highlighted in black because it overlapped with 
ETS binding site and was previously assayed successfully for epigenetic biomarker (Q. Xu, et al., 2010). 
(C) The SULT2A1 gene on the antisense strand exhibits variable methylation activity upstream and 
downstream of the TSS. The variable region at -1600 to -1900 bp is highlighted because it coincides with 







































(A) The CES2 assay examines 4 individual CpG sites located approximately 1600-1900 bp upstream of the 
TSS. The CES2 CpG site #3 is found within an ETS transcription factor-binding site. (B) The COMT assay 
covers 30 CpGs sites, although due to technical limitations (e.g. small fragment sizes are not detectable) 
Sequenom EpiTYPER outputs only 17 CpG units, spanning approximately 250 bp upstream and 100 bp 
downstream of the TSS. An ETS transcription factor binding site coincides with CpG sites #30 and #31 on 
COMT. (C) Although CpG methylation on the ETS consensus sequence of SULT2A1could not be directly 
assessed (CpG site #1), the assay investigates 6 individual CpG sites (4 CpG units) surrounding the target 
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5.1 Review of Dissertation Findings 
 The widespread apprehension over BPA and its health effects in our society today 
is primarily fueled by toxicology studies using animal and in vitro model systems, but the 
translatability of the findings to relevant human health risk continues to be a topic of 
extensive debate. The overall goal of this dissertation was to address BPA exposure-
outcome associations directly in humans, especially pertaining to the vulnerable fetus. 
Here, we utilized human clinical tissues obtained from elective pregnancy terminations to 
quantify in utero BPA exposure, understand fetal capacity for metabolism, and identify 
subtle exposure-dependent changes to gene expression and regulation important for 
biotransformation. 
 In chapter 2, we identified a wide distribution of BPA concentrations in the ng/g 
or parts-per-billion range within fetal liver specimens that changed with gestational age, 
indicating substantial yet variable fetal exposure during pregnancy. Metabolic potential 
for eliminating BPA in fetal liver differed from adult livers. Overall, we observed 
reduced hepatic expression of the BPA-specific metabolizing enzymes: UGT2B15, 
SULT1A1, and STS. When we explored differences in BPA toxicokinetics and 
toxicodynamics across fetal liver, placenta, and fetal kidney in chapter 3, we found 
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significant tissue-dependent differences in BPA concentrations, BPA-related metabolism 
gene expression, as well as global DNA methylation. Given the greater likelihood of 
BPA in fetal liver compared to matched tissue, we next examined exposure-dependent 
changes in gene expression and regulation of the biotransformation pathway only in the 
liver. In chapter 4, we identified over a dozen candidate XME genes that were down 
regulated with higher tissue BPA concentrations, all of which had common AP1 and ETS 
related transcription factor binding sites in the promoters. In a subset of these candidate 
genes, we identified increased methylation at biologically relevant promoter sites with 
increased BPA concentrations.  
 In general, findings from the entire dissertation can be compiled into two distinct 
sections: toxicokinetics (Figure 5.1) and toxicodynamics (Figure 5.2). Instead of 
employing classical toxicokinetic methods such as enzyme kinetics, we characterized 
tissue BPA concentrations and quantified gene expression of XMEs most relevant for 





 trimester human fetus is exposed to detectable concentrations of BPA in utero. 
Compared to adult liver tissue, BPA metabolizing enzymes are expressed at suboptimal 
levels in the fetal liver, which may explain the high free to conjugated ratio. Furthermore, 
greater expression of SULT1A1 in the sulfation reactions and GUSB in the 
glucuronidation reactions suggests that BPA-sulfate rather than BPA-glucuronide is the 
major conjugate in the fetus. In the latter half of the dissertation, we explore cellular 
responses associated with physiologically relevant concentrations of BPA, focusing on 
cis-acting regulatory markers and the genome.  While BPA concentrations and global 
methylation vary across tissue, the placental epigenome was most sensitive to exposure. 
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Focusing on pathway specific effects, BPA associated changes were noted for XME gene 
expression and methylation in fetal liver. These findings indicate that environmentally 
relevant concentrations of BPA, even across a short gestational window in the fetus, can 
cause detectable alterations in biotransformation programming.  
 
 
5.2 Significance  
 Over the past several years, regulatory agencies have determined that BPA may 
be potentially harmful for human development, especially for pregnant women, the 
developing fetus, and young children. While evidence for environmental exposure to 
humans is well established, studies that address how much BPA is reaching target sites 
and subsequently altering structure and function in these vulnerable populations are 
lacking. This dissertation project is noteworthy in that it is one of the first studies to 
reveal significant internal dose or exposure to tissue in developing humans and identify 
subtle changes in expression and regulation at target sites within the human fetus. In 
particular, BPA’s impact on the biotransformation pathway is important because it may 
contribute to inter-individual variations in succeeding drug and environmental toxicant 
response. Pharmacological studies have already considered nonlinear growth and 
maturation processes, genetic differences, and sex as important factors for shaping drug 
efficacy and toxicity, which is also relevant to environmental exposures (McCarver, 
2004). Results from this dissertation add to the complexity, demonstrating that early BPA 
exposure can alter metabolism and response to other nutrients, hormones, and xenobiotics 
that can influence proper development.  
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Furthermore, BPA’s relationship with XME signal transduction and epigenetic 
mechanisms has implications for xenobiotic response adaptations and susceptibility to 
diseases linked to toxicity, thus supporting the DOHaD hypothesis. Traditionally, 
pharmacogenomic studies have provided much of the evidence for the association 
between altered biotransformation capacity and adverse health outcomes, but the focus is 
shifting to prevalent environmental exposures. For example, studies now show that 
CYP1A1, GSTM1, and GSTT1 polymorphisms can alter polycyclic aromatic hydrocarbon 
metabolism and contribute to inflammatory processes that predispose individuals to 
atherosclerosis (Marinkovic, Pasalic, & Potocki, 2013). In the fetus, when xenobiotic 
metabolizing enzymes and transporters are not fully developed, genetic differences are 
less likely to explain variability in xenobiotic biotransformation. Thus, interest in 
epigenetic regulation of absorption, distribution, metabolism, and excretion is emerging 
(Klaassen, et al., 2011; Zhong & Leeder, 2013). The dissertation findings show 
preliminary evidence for environmental exposures and their influence on 
biotransformation programming in early development. Furthermore, this research fills an 
important knowledge gap in early life epigenetics given that investigation of global, 





human fetus is limited. In the future, studies that combine epigenetics with developmental 
toxicology or pharmacology will be important for the improvement of environmental risk 




5.3 Study Strengths and Limitations 
The use of state-of-the-art techniques for BPA quantification and epigenetic 
analysis is a major strength of this dissertation. Advancements in analytical chemistry 
over the past decade has allowed for better biomonitoring of environmental compounds 
with increased sensitivity and precision. While a variety of methods and matrices are 
utilized for BPA detection, the CDC has optimized on-line solid-phase extraction coupled 
to HPLC-isotope dilution tandem mass spectrometry for biomonitoring. With the limit of 
detection decreasing from 0.4 to 0.1 ng/mL over the years, this analytical method is 
recommended as a gold standard for urinary BPA measurements (L. N. Vandenberg et 
al., 2012b; Zhou, Kramer, Calafat, & Ye, 2014). The HPLC coupled ESI-MS/MS method 
used for this project, however, is one of the most sensitive techniques optimized for tissue 
BPA biomonitoring with LOQs at 0.1 and 0.05 ng/g.  Furthermore, we used the universal 
gene expression procedure, RT-qPCR, and novel next generation sequencing based 
methods to identify candidate genes and altered methylation patterns within our clinical 
samples.  
Using proper extraction methodology, careful experimental design, and 
validation, fetal samples were analyzed for biomarkers of exposure to inform 
environmental health.  Considering the sensitive nature of fetal biospecimens, our study 
included a higher sample size for chemical analysis in fetal liver (N=50) and across 
matched tissue (N=12), whereas analogous studies investigated BPA biomonitoring in 
only N=28 Canadian fetal livers and N=11 matched adult postmortem tissues (Cao, et al., 
2012; Geens, et al., 2012).  Furthermore, the dissertation aims attempt to address many 
questions that arise in the debate over BPA’s risk to humans with one particular 
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uncertainty being the role of deconjugating enzymes during BPA metabolism (Ginsberg 
& Rice, 2009). Here, we analyze gene expression of both conjugating and deconjugating 
enzymes to explain BPA speciation, a discreet but pertinent distinction for understanding 
metabolism and risk.     
 Another unique aspect to this dissertation research is the use of human fetal 
clinical specimen for BPA biomonitoring and toxicodynamics. Once human tissues are 
available with proper patient consent, clinical samples can be ideal matrices for 
identifying organ specific concentrations and physiological modifications relevant for 
humans. In fact, they eliminate the need for costly animal models that are often 
inappropriate for extrapolation to human. In the BPA biomonitoring field, however, some 
scientists are skeptical about the use of biobanked specimens. Even with the application 
of proper quality controls to prevent contamination during chemical analysis, there is 
room for uncertainty given limited patient data and information about tissue extraction 
processes. Reports suggest that free BPA contamination can occur from breakdown of 
surgical equipment and plastic lab ware, deconjugation of tissue BPA during storage, and 
ex vivo contributions from reagents like water (Dekant & Volkel, 2008; L. N. 
Vandenberg, et al., 2012b).  Interestingly, the study design and results from chapter 3 
suggest otherwise, demonstrating that BPA contamination is negligible or absent within 
our clinical cohort. Among individual subjects, matched tissues that have the same 
environmental and genetic characteristics are extracted at similar times and under similar 
conditions before storage. Thus, BPA contamination during surgical extraction should be 
equally distributed across matching tissues. Yet, 3 out of 12 subjects exhibited 
undetectable concentrations of free BPA in one matched tissue, indicating that the 
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measurements in the remaining tissues are reflective of endogenous levels rather than 
contamination. Any potential contamination from tissue processing may lead to only a 
small overestimation of free BPA measurements, but detection of conjugated BPA alone 
is quite worrisome as it suggests substantial in utero BPA exposure in the human fetus.  
 While we were fortunate to have access to valuable fetal specimen, there were 
several drawbacks to our study design using this clinical cohort. Due to the bioethical 
nature of the tissues, addressing our primary research goals over a wider gestational 
window including 3
rd
 trimester could not be feasible. Although rare, 3
rd
 trimester fetal 
tissues exclusively come from patients with morbidities and pregnancy complications, 
which could potentially confound any BPA exposure-outcome associations. Additionally, 
unlike other biomonitoring studies that only report free BPA or total BPA concentrations, 
separate analysis of free BPA and BPA conjugate concentrations consumed most of the 
tissue reserves. Therefore, subsequent biomolecular testing was limited to genetic 
analyses that require only a small sample volume. A major limitation of this project was 
the failure to account for cell specificity in expression and methylation. The cellular 
makeup of fetal organs can quickly change over a short period of time, especially by the 
end of 1
st
 trimester, as each cell population maintains a distinct expression and epigenetic 
trajectory (Gellen, 1976; Isagawa et al., 2011). For example, the fetal liver is composed 
of a heterogeneous mixture of hepatocytes and hematopoietic cells, with cell composition 
changing given the decrease in hematopoietic potential over time (Brunner et al., 2009). 
In this dissertation, we explored epigenetic and genetic analysis across homogenized 
tissues by the end of human organogenesis without considering cell composition or tissue 
location mainly because of cost and sample volume. Furthermore, many of the flash 
 
128 
frozen tissues characterized in this study are highly perfused with blood during prenatal 
development, so there is some uncertainty as to whether measurements are true tissue 
concentrations or include blood concentrations. Separation of blood and heterogeneous 
cells can be problematic, introducing exogenous BPA and altering structure and function. 
Nevertheless, technological advancements in cell sorting processes and cell-specific 
molecular analysis are ongoing, but are not yet cost effective for everyday use on 
precious specimen and unrealistic for samples with small volume.  
 
 
5.4 Future Directions 
The results and shortcomings from this dissertation bring to light new questions 
that must be tackled for future BPA research. Separating free BPA and BPA conjugates is 
just the first step, but biomonitoring projects must consider measuring different BPA 
conjugate species. Traditionally scientists have viewed BPA-glucuronide as the primary 
conjugate in adults, but new evidence suggests that BPA-sulfate conjugates may 
predominate in the fetus. In this study, we noted higher fetal liver SULT1A1 compared to 
UGT2B15 and STS expression, and a new study reported BPA-sulfate concentrations to 
exceed BPA-glucuronide and free BPA concentrations in midgestational umbilical cord 
serum (Gerona, et al., 2013). Ideally, we would measure both conjugates to corroborate 
our gene expression results across multiple fetal organs. Our collaborators at Wadsworth 
and other analytical chemistry labs are currently optimizing cost-effective techniques that 
simultaneously measure multiple BPA metabolites as well as BPA-like compounds.  For 
example, the CDC has begun to analyze BPA and 11 other similar phenols together in 
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urine (Zhou, et al., 2014), but similar chemical analyses will take longer to optimize in 
solid tissue matrices given the varying fat content. In the natural environment, people are 
exposed to several types of environmental contaminant. It is likely that these fetal 
specimen also exhibit detectable concentrations of phthalates and other phenols, with 
biological programming affected by co-exposure interactions. To investigate toxicant 
interactions and co-exposure toxicities in future environmental health research, 
improvements in sample processing and analytical techniques will be necessary.  
As mentioned previously, exposure-outcome associations require examination in 
a cell-specific and time-specific manner. Accounting for cell specificity using these 
sensitive clinical specimens will be difficult with the current technology, but other 
biological models are available. Studies using human cell lines derived from fetal tissue 
may be beneficial for determining BPA toxicity. Thus far, BPA is found to induce 
preterm associated corticotrophin-releasing hormones in placental JEG3 choriocarcinoma 
cells, and promote proliferation of human mammary epithelial cells from embryonic stem 
cells (Huang, Tan, Wang, & Leung, 2012; L. Yang et al., 2013). Unfortunately, primary 
human fetal cell lines are scarce, and methods for cell separation or isolation from fresh 
tissue can be tedious and low yielding. While these human cell lines may provide greater 
flexibility for BPA toxicity assays, they fail to emphasize in utero exposures and cell-cell 
interactions. Understanding BPA toxicity in the context of human organ ontogeny or 
development is far more complicated given bioethical challenges as previously noted. 
Comparing BPA concentrations with physiological changes over time in humans is 
limited to cross-sectional rather than longitudinal study designs.  In a recent review 
evaluating metabolism and transport ontogeny across species, changes in 
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biotransformation were reported through mRNA and protein expression with 
developmental data in the human fetus grossly underrepresented (Moscovitz & 
Aleksunes, 2013).  Thus, forthcoming research in toxicology will require new study 
samples and methodologies to address developmental biotransformation or ontogeny in 
humans.  
For subsequent research projects, our clinical specimens can still be valuable for 
addressing BPA accumulation, biotransformation regulation, and toxicological endpoints. 
In this dissertation, we measured BPA species across placenta, fetal liver, and fetal 
kidney because they have important functions in xenobiotic metabolism. Other fetal 
organs are also available in the lab and may be interesting to check for BPA 
accumulation. Since studies suggest that BPA can influence neuroendocrine and 
reproductive structure and function (Cantonwine, Hauser, & Meeker, 2013; Frye et al., 
2012), measuring BPA and metabolic potential in additional tissues like the fetal brain 
and fetal gonads may be informative. Comparison of various organs can help determine 
whether expendable tissues (i.e. blood, placenta) can act as a reliable substitute for target 
tissues that are hard to access (i.e. liver, brain, etc.). Furthermore, multi-organ 
comparison of BPA concentration within a handful of fetal subjects can support BPA 
physiologically based pharmacokinetic (PBPK) models for estimating tissue deposition at 
other gestational ages. In this dissertation, we examined the role of gestational age only 
for BPA concentrations in fetal livers and adjusted for age in many of our statistical 
models. We could characterize time-dependent exposure, expression, and epigenetic 
changes for each tissue type by increasing sample size and selecting samples across a 
wider gestational window.  
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The divergence in BPA concentrations across matched fetal tissues brings to 
question tissue-specific differences in factors other than phase I and II enzymes, 
including transporters and cofactor concentrations. In general, two large classes of 
transporters, the solute carrier (Slc) and ATP-binding cassette (Abc), are known for 
substance influx and efflux across different organs (Konig, Muller, & Fromm, 2013). 
Smaller uncharged molecules are more likely to favor passive diffusion, while bulky 
molecules like BPA-glucuronide require active transport. Thus far, studies report 
conflicting evidence for the P-glycoprotein (MDR) efflux transporter and its ability to 
bind free BPA in various cell lines (Jin & Audus, 2005; Yoshikawa et al., 2002). A recent 
study demonstrated that free BPA stimulated the MDR1, MRP2, and BCRP human efflux 
transporters and BPA-glucuronide stimulated MRP3 using ATPase activity assays 
(Mazur et al., 2012). Similar to phase I and II XMEs, expression of transporters likely 
differ throughout prenatal development; although, this is not well characterized in the 
developing human fetus. Our clinical fetal specimens can be a viable tissue to 
characterize transporters that specifically bind to BPA species, comparing expression 
across different gestational weeks and different tissue types.  Furthermore, if enough 
tissue is available, we can measure cofactors such as UDP-glucuronic acid and 3’-
phosphoadenosine-5’phosphosulfate (PAPS) across different tissue compartments. 
Combining research in xenobiotic metabolism, transporter, and cofactor concentrations 
analysis will provide an all-encompassing depiction of BPA internal dose in the 




5.5 Health Behavior and Policy 
 Toxicology studies using animal or in vitro models have traditionally been used to 
understand human health, but human clinical specimen are an incomparable asset that can 
be most informative for driving science policy. Currently, issues surrounding 
inappropriate translation across species and BPA contamination have lead to skepticism 
and doubt in BPA research. Addressing these concerns, findings from this study and 
other human studies directly support the 2008 National Toxicology Program (NTP) 
conclusions in that there is “some concern for developmental toxicity for fetuses, infants, 
and children” (Chapin, et al., 2008). Many of the BPA toxicities are subtle, indirect, or 
manifest at a later period. Whereas conventional policies are determined by factors that 
demonstrate obvious dangers to general human health, science-based regulations should 
now create specific guidelines that consider different populations, different chemical 
characteristics, timing, and low dose exposures. In doing so, many environmental 
compounds like BPA would become important contenders for stringent regulation.    
Although copious research surrounding BPA exposure and health has surfaced 
over the last two decades, opposition from influential chemical and plastic companies has 
brought BPA to the forefront of international debate. BPA’s desirable properties have led 
to the creation of a multi-billion dollar industry, supplying convenient products to a 
global consumer market.  Policies regulating this high-stake product is challenging given 
the economic cost and difficulty in finding safe chemical replacements. In the USA, 
regulatory agencies have been slow to determine safety levels, with the Environmental 
Protection Agency still inaccurately using the 1993 lowest observed adverse effect level 
at 50 mg/kg per bodyweight. Regulatory agencies across different countries and within 
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the USA display conflicting views on BPA; for example, in 2008 Health Canada declared 
BPA as a health hazard, while Food and Drug Administration announced that research for 
BPA risk was inconclusive (Erler & Novak, 2010; Resnik & Elliott, 2014). In general, 
stringent regulatory action against BPA is difficult especially since the social and 
economic costs to industry and health care agencies are unknown.  
In recent years, the growing public alarm over BPA risk have prompted several 
companies like Wal-Mart and Toys R Us to voluntarily stop the sale of different BPA 
containing products. Consumer response has driven manufacturers to investigate BPA 
substitutes and to ensure better labeling (Barraza, 2013). While some safe alternatives 
include glass, steal, and polypropylene, BPA synthetic alternatives like bisphenol-S and 
bisphenol-F are proving to be just as harmful as BPA (Chen, Ike, & Fujita, 2002; S. Lee, 
Liu, Takeda, & Choi, 2013). In general, health care providers and environmental 
advocacy groups have promoted behavioral changes to reduce exposures. Reducing 
canned food consumption, avoiding polycarbonate plastic storage containers to heat food, 
and using reusable BPA-free water bottles are some common recommendations for 
consumers. Until further legislation, the public must be kept informed about new 





 In this dissertation, identification of BPA species at different developmental 
periods and fetal tissues along with concentration-dependent changes in XME gene 
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expression and regulation signify considerable in utero BPA exposure and potential risk 
during pregnancy. The findings have implications across multiple disciplines, informative 
especially for developmental toxicology and pharmacology. In particular, this project 
sheds light on programming in early life to support the developmental origins of health 
and disease hypothesis. Additionally, application of sensitive and high throughput 
techniques to human clinical specimens help address natural exposures and biological 
changes that are most relevant to the human population. Thus, results are important for 
public health and policy not only important for BPA regulation but also useful for other 
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